Paris, France, 06/19/2025<h5 style="text-align: center">The <a target="_top" rel="" href="https://www.parissaclaycancercluster.org/">Paris-Saclay Cancer Cluster</a> (PSCC) and Future4Care have announced a strategic partnership to accelerate innovation in healthcare. This collaboration aims to enhance support for start-ups working at the crossroads of oncology and digital health by leveraging the strengths and networks of complementary ecosystems.&nbsp;</h5><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_00557_1_e24790570f.png" alt="DSC00557 (1).png" width="4240" height="2384">As the need for transformative healthcare solutions continues to grow, the PSCC remains committed to translating world-class academic research into innovative therapeutic and diagnostic industrial solutions for cancer patients. Future4Care, a leading European ecosystem in Healthtech , brings together industry leaders and start-ups to develop cutting-edge digital solutions for tomorrow's healthcare system.&nbsp;<h6></h6><h4>A shared ambition to accelerate innovation in healthcare&nbsp;</h4> This collaboration is founded on a mutual commitment to supporting companies operating at the intersection of oncology and digital health. Through coordinated efforts, PSCC and Future4Care will provide startups with access to a wide range of complementary resources, including:&nbsp;<ul><li>Cross-promotion of services and synergies across both ecosystems, with opportunities to participate in thematic sessions, co-organized events, and networking days hosted at each partner’s premises.&nbsp;</li></ul><ul><li>Enhanced visibility through joint communication initiatives, including social media campaigns, newsletters, and shared presence at key events.&nbsp;</li></ul><ul><li>Coordinated support for jointly accompanied startups, ensuring efficient resource allocation.&nbsp;</li></ul><ul><li>Priority access to PSCC and Future4Care facilities for eligible events organized as part of this partnership.&nbsp;</li></ul>&nbsp;Facilitating access to healthcare data&nbsp; Improving access to healthcare data is a shared priority for both PSCC and Future4Care, as it plays a key role in accelerating innovation. PSCC is currently developing a unified portal to simplify access to real-world data, in collaboration with leading hospital centers. At the same time, Future4Care supports startups and innovators in navigating the complex landscape of healthcare data and regulatory requirements.&nbsp;As part of their partnership, the two organizations will jointly launch surveys and working groups to better understand the needs of startups in oncology and e-health. They will also co-host thematic events focused on AI and data in oncology and co-develop tailored support tools and services for projects that align with both of their missions.&nbsp;"Through this partnership with Future4Care, we are significantly expanding the scope and quality of support we can offer to start-ups addressing oncology needs with digital health innovations," said Eric Vivier, President of the PSCC. "By combining our scientific and clinical expertise with Future4Care's strengths in digital innovation and industry partnerships, we are creating a seamless pathway for dual-domain projects. This collaboration will help accelerate the development of data-driven solutions that meet real clinical needs and ultimately improve patient outcomes."&nbsp;&nbsp;“At Future4care, we are firmly convinced that alliances between multidisciplinary players are key to shaping the future of healthcare, says Agnès de Leersnyder, CEO of Future4care. This is why we are delighted to partner with PSCC, whose mission and areas of expertise are highly complementary to our ecosystem.&nbsp; Together, we aim to foster new synergies for our members and help drive the success of innovative solutions that are already accelerating progress in oncology.&nbsp; I’m looking forward to seeing the concrete projects that will emerge from this collaboration.”&nbsp;&nbsp;***&nbsp;About the Paris-Saclay Cancer Cluster (PSCC)&nbsp;Founded by Gustave Roussy, Sanofi, Inserm, Institut Polytechnique de Paris, and Université Paris-Saclay, the PSCC is the first laureate of France 2030’s “Biocluster” call for projects. The PSCC is supported by startups, biotechs, and pharmaceutical companies and has already welcomed leading members such as UNICANCER, Institut Curie, AP-HP, and Medicen.&nbsp;The Cluster’s mission is to accelerate innovation in oncology and the development of new therapies, diagnostics, and medical devices in France.&nbsp; The PSCC supports project leaders at various stages of maturity by giving them access to the resources they need (expertise, platforms, services…) and by fostering strong collaboration among all stakeholders — researchers, experts, patients’ associations, clinicians, startups, industry players, investors — within a dynamic, high-potential ecosystem rooted in Villejuif.&nbsp;With an international outlook, the PSCC aims to position France as a global leader in transforming science into patient-focused solutions.&nbsp;🔗 <a target="_blank" rel="" href="http://parissaclaycancercluster.org">parissaclaycancercluster.org</a>&nbsp;About Future4care&nbsp;Future4care is a European ecosystem of multidisciplinary players dedicated to digital health. A joint venture founded in 2021 by the alliance of Capgemini, Generali, Orange and Sanofi, Future4care brings together E-health players (major groups, experts, healthcare professionals, startups, etc.) to create synergies and opportunities that will accelerate progress in digital healthcare. Since its launch, Future4care has brought together industrial and institutional partners, as well as qualified personalities from the scientific and cademic worlds within a Scientific and Ethical Council.&nbsp;🔗 <a target="_blank" rel="" href="https://future4care.com">https://future4care.com</a>&nbsp;Contacts&nbsp;&nbsp;Future4care :&nbsp;Justine Spitzer, head of Communications&nbsp;<a target="_blank" rel="" href="mailto:Justine@future4care.com">Justine@future4care.com</a>&nbsp;06 88 85 36 60&nbsp;

Oncology meets digital health:  The Paris-Saclay Cancer Cluster and Future4Care join forces to accelerate innovation 

<h4><a target="_parent" rel="" href="https://www.maddyness.com/2025/04/03/1414955/">Opinion piece originally published on Maddyness IA</a></h4>Artificial intelligence in healthcare is no longer a promise, it is a reality. Every day, it saves time for healthcare professionals, improves chances for patients, and assists caregivers. Yet, we have only tapped into a fraction of its potential.In France, 30% of hospital doctors' time is still absorbed by administrative tasks. Too much bureaucracy, too much time wasted, and too many outdated tools. Meanwhile, AI is already capable of easing up the burden on healthcare workers, thanks to startups like Medvir for diagnostics, Hopia for anticipating hospital flows, or Tandem Health, which allows caregivers to save up to two hours per day by drafting their medical reports.For patients, the advancements are spectacular. In silico clinical trials drastically reduce time and costs of drug development. DeepLife and WhiteLab Genomics accelerate the search for new therapies using AI and digital twins.For the more than 9.3% of caregivers in France, often forgotten, AI is also a revolution. Doctoome, for instance, simplifies navigation in the healthcare journey.France has everything it takes to be a global leader in digital health. We have the talent, researchers, startups, and industry. We have an emerging Tech Bio sector, which was recently strengthened by the partnership between Future4care, France Biotech, and France Deeptech.Yet, some barriers still need to be removed for the healthcare sector to fully harness the power of artificial intelligence.<h4 style="text-align: start">Access to health data: a matter of sovereignty and competitiveness</h4>Data is the fuel of AI in healthcare. However, in our country, it takes an average of nine months from the submission of a request to access the data. Today, French startups must train on American or Asian databases because they do not have access to French data. This is absolute nonsense: It slows down innovation and prevents us from creating solutions tailored to our public health needs. It jeopardizes our health sovereignty: in the event of restrictions on foreign databases, we would become dependent on non-European players. It reduces the attractiveness of our healthcare ecosystem: startups and investors are reluctant to establish themselves in France if data is not accessible.Emmanuel Macron’s announcement of massive investments in artificial intelligence and computing power during the Artificial Intelligence Action Summit marks a decisive turning point and demonstrates the national will to advance in the race for France's digital sovereignty. By equipping the country with high-density computing centers capable of hosting and processing massive volumes of data, this strategy will reduce our dependence on foreign infrastructures and ensure better protection of sensitive information. Beyond security, these investments will accelerate innovation in healthcare by facilitating the development of AI algorithms for diagnostics, research, and personalized medicine. In the current geopolitical context, mastering health data is a strategic lever, allowing France and Europe to take the lead in AI in life sciences.<h4 style="text-align: start">Modernizing hospital digital infrastructures</h4>Integrating AI solutions into hospitals remains a major challenge. Between the budget constraints of healthcare institutions, the complexity of regulations, change management, and the process changes brought about by digital transformation, the adoption of new technologies is often slowed down. The processes for approval and clinical validation are long and costly, complicating market entry for young companies. Furthermore, hospital infrastructures are often outdated and poorly suited for integrating advanced digital solutions. Lastly, the protection of health data, subject to strict requirements, adds an additional layer of complexity.As a result, it is still very difficult to deploy AI on a large scale in hospitals. A healthcare worker who has to juggle five different software systems will never be able to fully benefit from the advantages of new technologies.For AI in healthcare to fulfill its promises, it is essential to make it easier for startups to collaborate with healthcare institutions by streamlining collaborations and financially supporting the adoption of these innovations. AI cannot function without a solid foundation. The majority of French hospitals still operate with poor connectivity and outdated IT systems, with significant interoperability challenges. We must make the modernization of hospital digital infrastructures a national priority.<h4 style="text-align: start">Access to funding: Stay the course</h4>France is home to a rapidly growing HealthTech ecosystem, supported by massive public investments and increasing private sector engagement. The recent announcement of a €1.2 billion fundraising by the French investment firm Sofinova Partners is a promising new development for the sector. However, a major challenge persists: funding for startups after their Series A round. While the early stages of seed funding receive strong support, the transition to industrialization and international expansion remains a critical phase for startups, hindered by a lack of dedicated capital. It is imperative to strengthen the synergy between public and private funding to support this crucial transition. French health startups are not lacking in innovation or ambition, but they need investors ready to take over and transform their technological advancements into industrial and commercial success. Investors have a unique opportunity to participate in the consolidation of a strategic sector that offers both growth potential and societal impact. Now more than ever, it is necessary to accelerate the structuring of specialized funds for digital health and deep tech.It’s time for Europe to take responsibility and develop an ambitious funding strategy for healthtech and AI in healthcare.Inaction has a cost. A human cost, a financial cost, a strategic cost. We have the solutions, the talent, and the startups. It’s time to break down the barriers. At Future4care, we bring together startups, industrial players, hospitals, investors, and insurers to accelerate the adoption of digital health. Our goal is clear: to create European champions of digital health.France is at a decisive turning point in the race for AI, and we can no longer leave digital outside the healthcare system. AI in healthcare is not an option. It is an imperative!

Opinion piece by Agnès de Leersnyder for Maddyness: AI is already saving lives: France must take global leadership in digital health!

<h3>The Future4care Demo Day 2025: an exceptional day at the heart of healthcare innovation.</h3>On Thursday, March 13, 2025, the entire HealthTech ecosystem gathered at Future4care for a must-attend event—a true catalyst for innovation and business opportunities. Bringing together over 400 participants, the event showcased 60 startups from our ecosystem, including, for the first time, 18 startups from our latest international call for applications, who traveled from across the globe to be part of this unique moment.Attendees had the chance to explore an innovation village, fostering valuable exchanges between startups, experts, industry leaders, and investors.And for this 2025 edition, artificial intelligence was at the heart of all discussions.Dive into the world of digital health innovation and experience the energy of Demo Day 2025 with the aftermovie!<div data-youtube-video=""><iframe width="440" height="248" allowfullscreen="true" autoplay="false" disablekbcontrols="false" enableiframeapi="false" endtime="0" ivloadpolicy="0" loop="false" modestbranding="false" origin="" playlist="" src="https://www.youtube.com/embed/94wMvsh9Vow" start="0"></iframe></div>

Demo Day 2025: A Day Dedicated to Creating New Synergies

On March 5, 2025, Future4care had the pleasure of welcoming Swiss Life France employees for a Learning Expedition dedicated to the notion of responsibility, co-organized with Deloitte.Learning Expeditions are half-day workshops designed for companies, during which teams can discuss a specific theme with a delegation of start-ups selected by Future4care. It's an ideal format to engage teams and instill a culture of innovation.This enriching meeting was marked by three moments that highlighted the importance of a strategic vision and a concrete commitment to a positive and sustainable impact, particularly key in the healthcare sector: data confidentiality, equity of access to care and sustainability and adoption of technological solutions.<h4>Future4care: A Shared Vision for Transforming Healthcare Systems</h4>Agnès de Leersnyder, CEO of Future4care, opened the morning by sharing the background to the project and the shared vision of our four founders: Sanofi, Orange, Capgemini and Generali. This vision is based on the ambition of these major groups to facilitate the adoption and ethical use of artificial intelligence and digital technology to transform our healthcare systems and respond to the sector's major challenges: the acceleration of the search for new treatments and the development of new technologies.<h4>2-voice testimonial: Successful collaboration between start-ups and major corporations</h4>Pierre Le Corre, CEO of Music Care, and Stéphanie Faure, Innovation Project Manager at Generali, shared their views and feedback on a successful collaboration between a start-up and a major group. The two had worked hand in hand on a pilot study aimed at improving workers' well-being: reducing stress &amp; anxiety, sleep disorders and pain. The results demonstrated the value of deploying the solution more widely within Generali.<h4>Round table: Responsibility and impact of innovative healthcare companies</h4>3 entrepreneurs from the Future4care ecosystem then shared their experiences and perspectives on the notion of responsibility as a company serving healthcare. Their presentations highlighted concrete examples of the value and impact of their respective activities.Amélie Litrowski, CEO and founder of Doctoome, addressed the issues of health equity and access to care. Doctoome's mission is to support patients and their families throughout their healthcare journey. To this end, Amélie spoke of long-term collaborations with major groups that have improved the quality of care for patients, users and members. Today, the Doctoome platform covers 1.5 million patients.Alain Habra, CEO and co-founder of Quantiq, explained how their interoperable solution, which transforms any camera into a medical device for monitoring patient vitals, is an asset to a preventive healthcare approach. Through numerous partnerships with hospitals in France, Quantiq has facilitated clinical studies by integrating remote monitoring capabilities. Alain also emphasized the importance of the shared values of his team members.Gilles Litman, CEO of Remedee Labs, emphasized the importance of chronic pain management. Indeed, Remedee offers a non-drug solution for treating chronic pain using a millimeter-wave emitting bracelet. Gilles was able to describe how his solution has dramatically improved the quality of life of many users, clinically proven in particular for people suffering from fibromyalgia and osteoarthritis.<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_00294_1_b00b77f8e9.png" alt="DSC00294 (1).png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_00301_4c8935052f.png" alt="DSC00301.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_00426_2_3ace563279.png" alt="DSC00426 (2).png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_00333_2_7a97dfc3d1.png" alt="DSC00333 (2).png" width="4240" height="2384">

Learning Expedition: a morning of inspiration dedicated to responsibility and ethics

In January, Future4care launched the January4data campaign to highlight the essential role played by healthcare data in the value chain. To this end, we solicited the expertise of members of our ecosystem, which has given rise to these notes. The genesis of healthcare data, technological developments and uses, ethics and applications in the hospital sector are just some of the topics covered in this series of articles. &nbsp;&nbsp;Properly harnessed healthcare data, combined with rigorous and ethical artificial intelligence, have the capacity to implement precision medicine; a paradigm where care is tailored to each individual characteristics.&nbsp;With Scienta Lab, we aim to bring about the same revolution in the way we develop drugs, particularly for autoimmune diseases. These diseases, which affect around 10% of the world's population, are still poorly understood and difficult to treat.&nbsp;A patient-centered approach&nbsp;Autoimmune diseases such as lupus, rheumatoid arthritis and Crohn's disease are unique in their presentation in each patient.&nbsp;These chronic, incurable diseases have a major impact on the lives of their sufferers, with major, irreversible destruction of the affected organs, leading to disabling symptoms, increased risk of cancer and higher mortality.Unfortunately, current treatments are only marginally effective on a significant proportion of patients.&nbsp;Why? Because drugs are developed using a standardized approach that ignores the biological diversity of individuals.&nbsp;At Scienta Lab, we have chosen to tackle this challenge and enable the development of precision drugs for autoimmune diseases. Using data as a guide. We use health data from cells, animal models or patients to train our EVA foundation model, dedicated to immunology and inflammation.&nbsp;In this way, EVA acquires a representation of the immune system and its disorders, which is leveraged for personalized drug development. This precision medicine approach is at the heart of my vision of modern, equitable healthcare.&nbsp;Harnessing data to speed up decision-making&nbsp;In the field of artificial intelligence, the main difficulty is data accessibility. This is even more important in the healthcare sector. At Scienta Lab, we have developed an AI model specific to these constraints, and capable of extracting relevant information from small healthcare datasets.&nbsp;By studying targeted datasets and building adapted algorithms, we can answer complex questions such as:<ul><li>Will a drug work in humans, and why does it work in some patients but not in others?</li><li>Which drug candidate has the highest probability of passing clinical trials?</li><li>How can clinical trials be optimized to maximize efficacy and minimize costs?</li></ul>&nbsp;Partnerships to guarantee data quality&nbsp;An essential element of our success lies in our strategic partnerships with international hospitals and research centers. These collaborations give us access to high-quality healthcare data and ensure that our models reflect the diversity of patients with autoimmune diseases.&nbsp;We also invest in regular audits and validations to ensure the robustness of our algorithms and guarantee the security of personal data.&nbsp;Data ethics as a priority&nbsp;Europe, with initiatives such as the RGPD or the AI Act, enforces high standards on data protection and its exploitation in algorithms. These regulations impose significant constraints on innovation, but I believe they provide a necessary ethical framework to ensure that healthcare data is used for the benefit of all. I also believe that these regulations create opportunities and competitiveness for European start-ups by strengthening the confidence of patients and partners, while positioning Europe as a model of ethical innovation.<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/Bouget_Vincent_072_1112_c9af16dbd7.jpg" alt="Bouget_Vincent_072-1112.jpg" width="1365" height="2048">

Expertise note Vincent Bouget - Co-founder and Scientific Director of Scienta Lab

At the AI Action Summit Business Day held at Station F on Tuesday February 11, France Biotech, France Deeptech and Future4Care announced the signing of a strategic partnership agreement.Launched at the initiative of David Del Bourgo, CEO and co-founder of WhiteLab Genomics, this action aims to structure and develop the TechBio sector in France through the creation of a dedicated working committee. This new commission will be tasked with fostering collaboration between TechBio players, improving access to healthcare data - essential for these innovative companies - and structuring the French TechBio sector.&nbsp;<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/David_AROUS_5619_39bbbaa39a.jpg" alt="DavidAROUS-5619.jpg" width="2048" height="1365">At the signing ceremony, Frédéric Girard, President of France Biotech, Michel de Lempdes, President of France Deeptech and Agnès De Leersnyder, CEO of Future4Care, discussed the objectives of this strategic initiative, which follows on from the work of the “AI &amp; Biodiscovery” expertise group launched in 2024 by France Biotech, and more broadly the challenges of this emerging sector.&nbsp;“AI offers a major opportunity to accelerate drug discovery and development. By adopting these new technologies from the hard sciences, biotechs and pharmaceutical companies can accelerate and secure their R&amp;D for the benefit of patients, while reducing the cost, risk and timeframe of clinical developments,” said Frédéric Girard, President of France Biotech, underlining the importance of this collaboration in strengthening the French ecosystem and, ultimately, France's sovereignty.&nbsp;For Michel de Lempdes, President of France Deeptech, “this partnership is an essential step forward in structuring the development of TechBio in France. By bringing together the strengths of AI and biotechnology, we are creating a framework conducive to innovation, for the benefit of patients and the competitiveness of our sector.”Agnès De Leersnyder, CEO of Future4Care, comments: “This partnership is a key step in structuring this fast-growing market. Future4Care is delighted to support TechBio companies through its gas pedal, creating the right conditions for their integration into the pharmaceutical industry”.For David Del Bourgo, CEO and co-founder of WhiteLab Genomics, and co-coordinator of this new TechBio commission: “This commission was created to structure an economic ecosystem in a sector that is still little-known but extremely promising. We are fully committed to accelerating the development of TechBio companies, which are distinguished by their dynamism in France and actively contribute to the influence of innovation in our country”.&nbsp;TechBio: a booming industryTechBio makes it possible to better predict drug-target interactions, identify biomarkers and develop personalized treatments that are better adapted to patients. This sector, which combines advances in biotechnology and artificial intelligence, is booming in France. France Biotech's “AI &amp; Biodiscovery” expertise group, in partnership with companies such as Adlin Science, Orakl Oncology and WhiteLab Genomics, recently mapped the French players in this field.&nbsp;This study has enabled us to gain a better understanding of the economic and technological challenges facing these companies, as well as their financing and market access requirements. Today, the sector comprises some twenty French companies, most of which are focused on the development of proprietary assets. These innovations require privileged access to healthcare data, a strategic challenge for strengthening their international competitiveness.&nbsp;Working together to shape the future of healthcare innovationThanks to this joint working committee, France Biotech and France Deeptech, with the support of Future4Care, intend to promote synergies between startups, researchers, manufacturers and investors, to accelerate innovation for the benefit of patients and European healthcare sovereignty.&nbsp;About France BiotechFrance Biotech, founded in 1997, is an independent association that brings together entrepreneurs in healthcare innovation and their expert partners. As the driving force behind the 2,600-strong healthcare innovation ecosystem, and a privileged interlocutor for public authorities in France and Europe, France Biotech contributes to meeting the challenges facing the HealthTech sector (company financing, innovation taxation, regulatory issues and market access, etc.) and to proposing concrete solutions, in terms of competitiveness and attractiveness, through its commissions and working groups. France Biotech is housed at the PariSanté Campus. <a target="_blank" rel="" href="http://www.france-biotech.fr/">http://www.france-biotech.fr/</a> Press contact: France Biotech // Florence Portejoie, FP2COM, <a target="_blank" rel="" href="mailto:fportejoie@fp2com.fr">fportejoie@fp2com.fr</a>, 06 07 76 82 83&nbsp;About France DeeptechFrance Deeptech is an association created in 2023, open to all deeptech players in a logic of ecosystem, partnership and healthy creative emulation. Its objective is to bring together and federate the various players in the French and European deeptech sector, in particular entrepreneurs, deeptech investors and research laboratories, in order to encourage the emergence and/or rapid growth of ambitious and daring entrepreneurial projects capable of making a decisive contribution to solving major contemporary challenges, and maintaining French and European competitiveness and technological independence, which are key to sovereignty and freedom.&nbsp;About Future4careFuture4care is a European ecosystem of multidisciplinary players dedicated to digital health. A joint venture founded in 2021 by the alliance of Capgemini, Generali, Orange and Sanofi, Future4care brings together E-health players (major groups, experts, healthcare professionals, startups, etc.) to create synergies and opportunities that will accelerate progress in digital healthcare. Since its launch, Future4care has brought together seven industrial and institutional partners (Alira Health, Be-ys, Biocodex, Elior, Havas Life, TNP, UCB and FEHAP) and qualified personalities from the scientific and academic worlds within a Scientific and Ethical Council.&nbsp;About WhiteLab GenomicsWhiteLab Genomics, a pioneer in the accelerated development of genomic medicine, stands at the convergence of computer science and biology. Founded in 2019 and backed by YCombinator, it is establishing itself as a key player in genomics innovation. Its platform provides in silico simulations to discover and design optimized therapies. WhiteLab aims to accelerate the drug development process, reduce costs and bring genomic medicines to market faster. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions and innovative biotech companies. WhiteLab Genomics is part of the prestigious French Tech 2030 program supported by the French government, and recently joined the Bayer Co.Lab in Cambridge, Massachusetts.

France Biotech, France Deeptech and Future4Care join forces to accelerate the development of TechBio in France.

In the latest episode of our Future4care Inside series, we hear from Didier Cadic, Head of Innovation at Generali France.&nbsp;Didier talks about the link between Generali France and the startups in our ecosystem, and shares his vision of innovation. Generali's challenge as a health insurer is to focus on prevention.&nbsp;“The uniqueness of Future4care is the connection between these players with industrial projects that see the light of day”<div data-youtube-video=""><iframe width="440" height="248" allowfullscreen="true" autoplay="false" disablekbcontrols="false" enableiframeapi="false" endtime="0" ivloadpolicy="0" loop="false" modestbranding="false" origin="" playlist="" src="https://www.youtube.com/embed/yL2vwmeVUX0" start="0"></iframe></div>&nbsp;Thanks again to Didier Cadic for this interview!

Future4care Inside: A testimony from Didier Cadic, Head of Innovation at Generali France

In January, Future4care launched the January4data campaign to highlight the essential role played by healthcare data in the value chain. To this end, we solicited the expertise of members of our ecosystem, which has given rise to these notes. The genesis of healthcare data, technological developments and uses, ethics and applications in the hospital sector are just some of the topics covered in this series of articles. &nbsp;&nbsp;I'm convinced that hospitals in France play a crucial role, built around three fundamental pillars: care, teaching and research. It's a complex mission, and the rapid evolution of technology, particularly in the field of artificial intelligence (AI), is profoundly transforming these activities. Today, we are witnessing a veritable explosion of data and technological capabilities, creating immense possibilities but also raising questions of interoperability, quality and security.&nbsp;The integration of data into hospital structures is nothing new. For over fifteen years, biobanks and associated databases have played a major role in medical research. However, we now understand that simply accumulating biological data, without enriching it with contextual information (imaging, therapeutic strategies, pathological trends), is insufficient. The richness of data lies in its quality, granularity and interconnection. Clearly, without precise structuring and a coordinated effort to improve their quality, these data cannot fully meet the needs of modern healthcare.&nbsp;Unprecedented technological evolution&nbsp;Advances in computing and storage capacities, notably with the emergence of quantum computing, are revolutionizing the way we approach data processing. This technological evolution makes it possible to process massive volumes of information with greater precision and speed. For example, modern AI models can analyze data in seconds that would take months to process manually. But what does computing power matter if the data processed is incomplete or of poor quality? This question illustrates one of the main challenges we face: data interoperability and relevance.&nbsp;Take medical imaging, for example. The widespread use of MRIs and scanners, combined with ever more powerful capture tools, has democratized access to massive volumes of data. However, without a rigorous labeling process, an MRI image can only be partially exploited. It is the human expert who must, for example, identify and delimit a tumor to enable the AI to train accurately. This crucial step, known as labeling, is often underestimated, but is the foundation of any reliable analysis.&nbsp;Increased storage capabilities also enable a complete patient history to be maintained, including genomic data, medical history and interactions with different treatments. This paves the way for unprecedented personalization of care, but only if this data can be exploited and interconnected between different healthcare systems.&nbsp;The challenges of data quality and security&nbsp;Beyond simple acquisition, there are challenges linked to data management and processing. Biases in acquisition mechanisms, artifacts and extrapolation problems can all affect data quality. Take a concrete example: data from the same patient may vary according to the machines used or the protocols applied, introducing differences likely to bias analysis results.&nbsp;What's more, interoperability between different hospital systems remains a major challenge. For example, the same patient being treated in several different facilities can generate data that is scattered and difficult to correlate. These shortcomings hamper a global and coherent vision of the care provided.&nbsp;Another major challenge is data security. In a society oscillating between trust and mistrust, it is vital to strike a balance. Too many restrictions hinder access to data, even for noble objectives such as research or public policy. I've been confronted with this complexity myself: the delays and constraints imposed by systems such as CASD (Centre d'accès sécurisé aux données = Secured data access center) are often a deterrent. Yet these restrictions do not always prevent data leaks, often caused by trivial human error.&nbsp;Furthermore, examples of medical data leaks remind us of the importance of re-evaluating our systems. Some recent leaks have highlighted flaws in internal access management, underlining the need for stronger auditing and accountability protocols.&nbsp;The role of ethics in healthcare data management&nbsp;Ethics play a central role in our approach to health data. It guides us when the law is silent. But too much control can have the opposite effect, fueling conspiracy and holding back projects. We need to ask ourselves: is it ethical not to fully exploit available technologies to improve public health?&nbsp;The ethical framework is also crucial for regulating the use of AI in analysis processes. Take the case of machine learning algorithms: how can we ensure that they do not introduce systemic biases? Ethics must also address the dilemmas linked to the balance between innovation and personal data protection.&nbsp;ConclusionData is at the heart of the evolution of our healthcare system. If we are to harness its full potential, we need to rebalance our approaches between openness and protection, while ensuring that strong ethics are maintained. It's time to meet the organizational, technological and ethical challenges to build a future where healthcare is accessible, innovative and secure.<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/image_18_6adc797844.png" alt="image (18).png" width="1204" height="1953">

Expert opinion Julien Rutard, Vice President, Healthcare Sector (Capgemini Invent) - Data in the hospital environment

In January, Future4care launched the January4data campaign to highlight the essential role played by healthcare data in the value chain. To this end, we solicited the expertise of members of our ecosystem, which has given rise to these notes. The genesis of healthcare data, technological developments and uses, ethics and applications in the hospital sector are just some of the topics covered in this series of articles.&nbsp;What is your perspective on the use of healthcare data?&nbsp;For over five decades, I've witnessed and played an active role in major developments in the field of healthcare data. My work has always been driven by the conviction that quality data are essential for decision-making and research in general, and particularly for research into rare diseases, a field that Orphanet has been instrumental in helping to develop.&nbsp;When I began my career in the 1970s, the landscape of data collection and organization was sparse and unstructured, limited to research survey data due to the lack of accessible technology for digitizing real-life data. Moreover, there was no standardization of nomenclatures, which was a major obstacle to collaborative research.&nbsp;The emergence of medical informatics in the 1980s enabled progress to be made. Medical records are coded using the ICD, the WHO's international classification of diseases. The ICD listed around a hundred diseases in the XIXᵉ century, several thousand today. However, genetic diseases and rare non-genetic diseases were largely absent from this classification. &nbsp;The ICD 11 currently in use contains only 450 of these, and Orphanet has helped to introduce another 4,500 into the ICD 12 adopted by the WHO, but unfortunately not yet in use, as changing versions is costly for public players.&nbsp;At the same time, in 1966, Victor McKusick proposed the Mendelian Inheritance in Man (OMIM) catalog of human genes and genetic diseases, a nomenclature widely used in research, but which does not enable diseases to be properly coded, as some diseases are caused by multiple genes, and some genes can be the cause of several diseases.&nbsp;Drawing on my long experience in genetic epidemiology and medical genetics, I founded Orphanet in 1997, a relational, exhaustive and polyhierarchical database that considers different perspectives and reconciles the various existing nomenclatures. Today, Orphanet lists more than 11,000 rare diseases and offers classifications adapted to the specific needs of research, care, public health and the pharmaceutical industry. Orpha codes enable diseases to be coded either zoomed out (broad categories useful for health system management) or zoomed in (molecular level essential for biomedical R&amp;D).&nbsp;What are the challenges facing the use of healthcare data?&nbsp;It took a long time for medical informatics to be used, due to a lack of awareness among doctors and decision-makers, but above all because of the cumbersome nature of the equipment, the cost of the technologies and the lack of user-friendly access to the data.&nbsp;The data collections that were built up presented problems of data quality and interoperability. The databases were disparate and poorly structured, limiting their usefulness. At the same time, the constraints imposed by national and European regulations, although justified to protect nominative personal data, have complicated the use of data for research, even though they are always pseudonymized. Is it justified to protect such data to the extreme, when the risk of re-identification is extremely low, and the potential damage caused low? This position, prevalent in Europe but taken to extremes in France, slows down research, or even hinders it, even though these are desirable projects for public health, improved care and innovation. This is detrimental to clinical research in general, and industrial clinical research in particular.&nbsp;An emblematic example concerns genetic data, often considered as indirectly identifiable, which prevents their systematic digitization in medical files, even though this is key information for both care and research. Doctors circumvent these restrictions by scanning the paper results they need for care, an inefficient practice that compromises both the usefulness and security of the data.&nbsp;How do you see the future of healthcare data?Today, we have the technological tools and infrastructures to collect and analyze quality data, thanks to the construction of healthcare warehouses and the existence of cohorts, registers and research databases. However, this potential remains under-exploited due to a lack of regulatory harmonization, sufficient investment, operator training and psychological resistance. Primary health data must be protected, but pseudonymized secondary data must be reasonably released. There is no known experience of collective or individual harm resulting from the use of pseudonymized data. On the other hand, the benefits of using such data can be significant for the community (e.g. relevance of care, prevention of health scandals, evaluation of innovations) and for the individual (e.g. development of new treatments), as well as having an impact on the individuals themselves. The benefit/risk balance is therefore very much in favor of the benefits. What remains to be done is to remove the obstacles to moving towards a one-stop shop. We need to stop communicating only about risks and not benefits, even though well-informed citizens are in favor of using their data for research. An audit of the obstacles to research in the current system would be useful to convince the reluctant.&nbsp;The European health data space represents a major opportunity for us in France, as we have already structured the recommended national node. This is the Health Data Hub.&nbsp;Together, we can build a future where data is used to save lives and improve public health. There is widespread public support for this approach.<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/image_17_63bea84501.png" alt="image (17).png" width="3839" height="2158">

Expert opinion by Ségolène Aymé, medical geneticist and world authority on rare diseases, founder of Orphanet

On November 7th, Future4care was thrilled to welcome Ipsen’s Global Patient Affairs team for an engaging workshop centered on pioneering patient-driven approaches. This event focused on positioning patients at the heart of medical progress and strengthening the voice of the patient community throughout clinical development and beyond.&nbsp;Why Patient-Centricity MattersTraditionally, patients have had limited influence in healthcare decision-making. However, as the industry evolves, patient-centricity has emerged as a foundational approach in clinical development and patient care. This shift emphasizes the importance of considering patient needs, experiences, and insights in every stage of drug development—from research to post-market engagement. By aligning treatments with real-world patient challenges, patient-centric approaches lead to better health outcomes, greater satisfaction, and stronger trust between patients and healthcare providers.Building a More Inclusive Approach to MedicineInclusivity in medicine means ensuring that treatments reflect the diverse needs of various patient communities. By actively listening to these unique experiences, healthcare companies can design therapies that are more accessible and relevant across different populations. An inclusive approach helps bridge gaps in healthcare access, literacy and understanding, ensuring that medical advancements truly benefit everyone. This commitment to inclusivity is essential for building a healthcare system that meets the needs of all patients, regardless of background, geography or circumstance.Future4care’s Role in Fostering InnovationAt Future4care, we believe that collaboration is the key to unlocking innovation, and this workshop with Ipsen’s Global Patient Affairs team is an example of our mission in action. As a dynamic hub for health and technology, Future4care brings together large companies, startups, and research institutions to co-create solutions that address pressing health challenges. We are proud to support our partners in developing a healthcare ecosystem that prioritizes patient voices, enhances collaboration, and fosters inclusivity.Join us on our journey to redefine the future of healthcare—one patient-centered innovation at a time!<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09854_524e58fb06.png" alt="DSC09854.png" width="4035" height="2384">

Workshop with Ipsen Global Patient Affairs Group: Advancing Patient-driven approches in clinical trials and beyond

Demographic transition and ecological transition: two unavoidable challenges for our societyOver the next 30 years, our society will face two major challenges:🌍 The climate, energy and environmental transition is an issue that is now omnipresent in the news. Global warming, loss of biodiversity, depletion of natural resources... these are all issues that call for urgent, coordinated action on a global scale. We're already seeing the effects of these changes, and the need for adaptation and innovation is stronger than ever.👵 Demographic transition is an equally crucial, if often less visible, challenge. A rapidly aging population is driving an exponential rise in demand for healthcare and healthcare services, while putting further pressure on already fragile systems. Our societies need to anticipate this development to guarantee high-quality care while preserving individual autonomy. The impact of aging on our healthcare system: Prof. Olivier Guérin's analysisProfessor Olivier Guérin, PU-PH and Head of the Rehabilitation Autonomy Ageing Unit at Nice University Hospital, President of the Collège National des Professeurs de Gériatrie, and Vice-President of Future4care, highlights the challenges posed by an ageing population to our healthcare system. In his view, the increase in life expectancy, coupled with the chronic illnesses that often accompany aging, is creating a growing gap between care needs and our ability to meet them.To meet this challenge, two priority areas are emerging:📋 Prevention: When it comes to healthcare, anticipation has become essential. At a time when our ability to meet care needs is increasingly uncertain, it is imperative to promote preventive practices, encourage a healthy lifestyle, and identify risks at an early stage to reduce the demand for intensive care. Prevention will limit pressure on healthcare infrastructures and ensure a better quality of life for individuals.🚀 Digital solutions in healthcare: technological innovation is becoming essential to fill the gaps in our healthcare system. Cutting-edge technologies such as artificial intelligence, robotics, and teleconsultation platforms can make up for the shortage of caregivers, improve the efficiency of services and offer more personalized care. These tools also make it possible to monitor patients remotely, reduce travel and offer ongoing support to aging populations.Future4care's commitment to the future of healthcareAt Future4care, we are convinced that innovation in digital healthcare can positively transform our society and meet the challenges of demographic transition. Our mission is to develop concrete solutions adapted to tomorrow's needs.<div data-youtube-video=""><iframe width="440" height="248" allowfullscreen="true" autoplay="false" disablekbcontrols="false" enableiframeapi="false" endtime="0" ivloadpolicy="0" loop="false" modestbranding="false" origin="" playlist="" src="https://www.youtube.com/embed/wlI_mODBDD8" start="0"></iframe></div>

Demographic transition, with Olivier Guérin

On October 14th, Clarissa Guengant had the honor and pleasure of welcoming the Minister of Health of Yemen, Dr. Qasem Buhaibeh, as well as Georges-Fabrice Blum, Deputy Health Federator for Exports, the French Healthcare Association and a delegation of French companies to discuss patient care in conflict zones 🦺 exploring innovative solutions developed by French companies to improve access to healthcare.&nbsp;<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/ministre_yemen_a47ecf1875.PNG" alt="ministre yemen.PNG" width="850" height="440">

Visit from the Minister of Health of Yemen

Thrilled to share this testimonial from Kwame Amaning, SanofiKwame Amaning, Digital Innovation &amp; External Ecosystem Lead at Sanofi, shares what it truly means to be part of the Future4care ecosystem, the power of collaboration, innovation, and shared purpose in advancing healthcare solutions for everyone. Thank you, Kwame, for your kind words and for being a key part of this journey!<div data-youtube-video=""><iframe width="440" height="248" allowfullscreen="true" autoplay="false" disablekbcontrols="false" enableiframeapi="false" endtime="0" ivloadpolicy="0" loop="false" modestbranding="false" origin="" playlist="" src="https://www.youtube.com/embed/7pJA487qdUs" start="0"></iframe></div>

Testimonial from Kwame Amaning, Sanofi 

Investing in digital means investing in health for everyone. The cost of inaction in healthcare is the worst one, and the longer we wait, the higher it will be, in lives as well as in missed opportunities to innovate.”In an opinion column published on September 24th, 2024 in the newspaper “Les Echos”, our CEO Agnès De Leersnyder urges the urgent integration of digital technology into our healthcare system. Despite its immense potential, digital technology is still insufficiently used in the sector, even though it is a crucial lever for accelerating the development of new treatments, optimizing caregivers’ time, personalizing care or even supporting caregivers.You can find the full article attached.

Opinion Column in "Les Echos": "Healthcare: the urgence of digital technology"

On September 25th, 2024, Future4care hosted a “Meet &amp; Greet” cocktail to celebrate the return to the office for the Future4care ecosystem, through informal meetings with members of our Scientific and Ethical Committee (CSE), chaired by Pr. Olivier Guérin.&nbsp;It was a real opportunity for exchange between members of the CSE, our founders, our partners, as well as CEOs of startups of Future4care’s ecosystem. Exciting discussions took place regarding ethical challenges of emerging technologies, management of sensitive data, and the impact of innovation on the healthcare system.&nbsp;<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/1_1a722703ed.png" alt="1.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/4_6564705647.png" alt="4.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/5_546865cad3.png" alt="5.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/3_62d380d083.png" alt="3.png" width="3814" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/2_b895485799.png" alt="2.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/6_7192e41471.png" alt="6.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/7_e27253a6d9.png" alt="7.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/8_e34957c75d.png" alt="8.png" width="4240" height="2384">

Meet & Greet: Back to School Cocktail with Future4care's Scientific & Ethical Committee

On September 25, the Be-Ys group, one of Future4care's long-standing partners, presented its reverse pitch to the ecosystem. A pioneer in digital trust and sensitive data management, Be-Ys offers a secure, accessible, and sovereign digital ecosystem, creating new opportunities for innovation.&nbsp;Their goal: to democratize the identity wallet, allowing individuals to control and protect their personal information, whether for sharing health data, accessing services, or conducting transactions. This model strengthens trust and transparency in digital exchanges, while ensuring compliance with regulations.&nbsp;BeYs provides a secure, accessible and sovereign digital ecosystem, while creating new opportunities for innovation. Data Annotation and AI use cases in healthcare were also shared: chatbot for patient triage, NLP for medical text analysis / information extraction from medical analysis reports, facial expression annotation for remote monitoring, etc.Many thanks to the BeYs team for their trust and commitment. Together, we look forward to shaping tomorrow's healthcare with solutions based on security and protection of sensitive data, while making healthcare technologies more accessible to all.<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_03794_d3236e5d04.png" alt="DSC03794.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_03759_da991ec6b1.png" alt="DSC03759.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_03819_48be0ec12f.png" alt="DSC03819.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_03845_bd1b7671cf.png" alt="DSC03845.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_03891_dc32719b0f.png" alt="DSC03891.png" width="4240" height="2384">

Reverse Pitch Be-Ys at Future4care 

We are thrilled to welcome new gems at Future4care!&nbsp;It is wonderful to see our Accelerator program grow with new promising startups, each of them bringing their own unique approach of innovation in digital health. Read about the latest talents that joined our venture:&nbsp;&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW62278461 BCX0" href="https://www.linkedin.com/company/adlin-science/">ADLIN Science</a> supports researchers through a collaborative platform that aims to structure and enhances their scientific data, therefore improving precision medicine.&nbsp;&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW62278461 BCX0" href="https://www.linkedin.com/company/axelife-sas/">AXELIFE</a> accelerates the measurement of cardiovascular risk with their device pOpmètre®, a non-invasive, non-operator-dependent solution for assessing arterial stiffness.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW62278461 BCX0" href="https://www.linkedin.com/company/biolevate/">Biolevate</a> uses generative AI in order to accelerate medical redaction and improve knowledge management in the pharmaceutical sector.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW62278461 BCX0" href="https://www.linkedin.com/company/boyd-sense/">BOYDSense</a> reinvents Diabetes monitoring with a non-invasive device that measures blood glucose via breath, offering simple and accessible follow-up.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW62278461 BCX0" href="https://www.linkedin.com/company/gmt-science/">GMT Science</a> provides robust, reliable and precise microbiome analysis with AI-based algorithms in order to improve the management of chronic disease.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW62278461 BCX0" href="https://www.linkedin.com/company/hometrix-health/">Hometrix Health</a> offers through their project AITIO a digital companion for patients with long term diseases, bringing them motivation and validated information through an intuitive app.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW62278461 BCX0" href="https://www.linkedin.com/company/seqone/">SeqOne</a> Genomics democratizes access to personalized medicine thanks to its genetic sequencing platform, enabling laboratories to offer large-scale precision diagnostics. &nbsp;We are delighted to welcome these new startups to our ecosystem and look forward to collaborating with them and supporting their growth!&nbsp;

New Start-Ups

On September 20, 2024, ThIA Santé Mental held expert roundtables at Future4care, in the presence of Generali teams, to discuss innovation in mental health. Psychologists, psychiatrists, researchers, representatives from the French Ministry of Health and the Caisse Nationale de l'Assurance Maladie, as well as clinic groups, manufacturers, insurers, financiers and investment funds, came together to share their vision and combine their efforts.&nbsp; &nbsp;Their objective? To transform care practices and tools for the 13 million French people affected by mental disorders every year. &nbsp;The Time 4 Mental Care initiative aims to unite these players around this crucial societal challenge. &nbsp;The coming year promises to be full of challenges, and we are determined to work together to build a future where patients are at the heart of our approach.&nbsp; &nbsp;Our ambition is to provide faster, better and sustainable care, thanks to technology at the service of people.&nbsp;

Time4MentalCare, by Thia Santé Mentale 

On September 19th, 2024, our CEO Agnès de Leersnyder was invited to take part in the event “Healthtech: worldwide innovations”, organized by <a target="_blank" rel="" class="Hyperlink SCXW174538299 BCX0" href="https://www.linkedin.com/company/frenchfounders/">Frenchfounders</a>, next to <a target="_blank" rel="" class="Hyperlink SCXW174538299 BCX0" href="https://www.linkedin.com/in/jeremie-weber/">Jérémie Weber</a> from <a target="_blank" rel="" class="Hyperlink SCXW174538299 BCX0" href="https://www.linkedin.com/company/institutcurie/">Institut Curie</a> and <a target="_blank" rel="" class="Hyperlink SCXW174538299 BCX0" href="https://www.linkedin.com/in/antonin-morillon-16b43b59/">Antonin Morillon</a> fromCereus Biosciences.&nbsp;Innovation in healthcare is more dynamic than ever and is an essential lever to make real deep changes in our healthcare system. At Future4care, we are convinced digital technology is key to unlock numerous opportunities, notably to:&nbsp;&nbsp;Accelerate research and development of new treatments and drugs,&nbsp;&nbsp;Improve diagnosis tools with better and clearer analysis&nbsp;Personalize care and treatments, developing therapies tailored for each patient&nbsp;Optimize medical time with automation of administrative &amp; repetitive tasks&nbsp;Better support for caregivers and relatives, with adapted follow up and management tools.&nbsp;We give many thanks to <a target="_blank" rel="" class="Hyperlink SCXW174538299 BCX0" href="https://www.linkedin.com/in/melanie-perrin-2508/">Mélanie Perrin</a> &amp; the whole team of <a target="_blank" rel="" class="Hyperlink SCXW174538299 BCX0" href="https://www.linkedin.com/company/frenchfounders/">Frenchfounders</a> for this beautiful invitation, that was also an opportunity to meet with French-speaking leaders from around the workd. These exchanges are vital for us to build together the future of healthcare, allying innovation, collaboration &amp; impact.&nbsp;

Healthtech : Worldwide innovations – intervention by Agnès De Leersnyder 

Congratulations to Remedee Labs!&nbsp;We are proud to see one of our startups, Remedee Labs, achieve a major milestone with the CE marking of its endorphin stimulator bracelet, the first medical solution in Europe dedicated to the treatment of fibromyalgia.&nbsp;A historic breakthrough for the millions of people affected by this disease, without any specific treatment until now. We can’t wait to see what happens next in this wonderful adventure, with a launch scheduled for 2025, and steps underway to make this solution accessible to as many people as possible.&nbsp;

Remedee Labs - CE marking of endorphin stimulator bracelet

This week, associates from <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/bpce-solutions-informatiques/">BPCE Solutions informatiques</a> visited <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/future4care/">Future4Care</a> in order to find inspiration and share their own vision in a setting where both our sectors, health and finance, naturally interact. One of the high points of this meeting was the interview of the CEOs of 5 startups, each specialized in digital healthcare, and from the ecosystem of <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/future4care/">Future4Care</a> ; each one of them contributing in their own special way to the transformation of our healthcare system.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/in/ritterdaniel/">Daniel Ritter</a> from <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/better-world-collective-intelligence/">Better World - Collective Intelligence</a> discussed the importance of collecting feedback from patients and healthcare professionals in order to retrieve exploitable information.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/in/amelie-litrowski-2337652/">Amelie Litrowski</a> from <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/doctoome/">Doctoome</a> revolutionizes prescription and personalized care pathways.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/in/julien-delpech-entrepreneur-healthcare-invivox/">Julien Delpech</a> from <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/invivox/">INVIVOX</a> shared his vision of democratizing access to to improve the quality of patient care worldwide.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/in/pierremlecorre/">Pierre Le Corre</a> from <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/music-care/">Music Care</a> revealed how musical composition algorithms reduce pain and anxiety in patients.&nbsp;<a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/in/lionel-guerin-978b031/">Lionel GUERIN</a> from <a target="_blank" rel="" class="Hyperlink SCXW228905548 BCX0" href="https://www.linkedin.com/company/scienceone/">ScienceOne</a> presented their cutting edge approach of automation of ecientific environment monitoring.&nbsp;Now more than ever, innovation and collaboration are key in transforming the healthcare landscape. Together, we continue to explore how these leaders build and put in motion their strategic vision, how the confront innovation, and how they imagine the future of healthcare.&nbsp;<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09355_1_89face62d1.jpeg" alt="DSC09355 (1).jpeg" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_01773_c3e722640f.png" alt="DSC01773.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_01783_368204f6c7.png" alt="DSC01783.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09603_ee698650a1.png" alt="DSC09603.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09578_6cee226422.png" alt="DSC09578.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09509_4a354a4822.png" alt="DSC09509.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09624_794e63752f.png" alt="DSC09624.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_01744_c2c153d731.png" alt="DSC01744.png" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09459_b7d8e3ec9d.png" alt="DSC09459.png" width="4240" height="2384">

Learning Expedition - Program UP by BPCE

On August 29, the Future4care Academy had the privilege of organizing a Boot Camp focused on Go-to-Market strategy in digital health, and we're delighted to share the highlights of the day with you! &nbsp;&nbsp;This #BootCamp was a real success thanks to the collaboration of all the participants and expert speakers! &nbsp;&nbsp;A digital healthcare solution can only benefit the greatest number of people if it has a well-thought-out Go-to-Market strategy right from the concept phase. And this is one of the aims of the Future4Care academy: to work on real-life cases to enable the manufacturers in its ecosystem to bring healthcare innovations to scale. &nbsp;Each participant left with a booklet, exercises and strategic action sheets to help them question their own innovation projects. &nbsp;This type of gathering is at the heart of the Future4care Academy's DNA, as it fosters collaborative innovation, accelerates the development of concrete digital health solutions, and strengthens synergies between the many players in the digital health value chain represented within the Academy, and always, with the advice and testimonials of our invaluable experts. Thanks to Norman Bodet Nextep Health, Christophe Brun Betterise Health Tech, Nicolas Naïditch, Ph.D ExpectPatient, Sarah Amrani Ethik IA. &nbsp;Please do not hesitate to contact Claire Patouillet, MBA, to discuss any of the topics covered at the event, or for any other topics you would like to see discussed.&nbsp;<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09355_1_89face62d1.jpeg" alt="DSC09355 (1).jpeg" width="4240" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/IMG_1280_82ecb63b3e.jpg" alt="IMG_1280.jpg" width="521" height="480"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09413_1_53cac61222.jpeg" alt="DSC09413 (1).jpeg" width="2566" height="2384"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/IMG_1273_82c4c62188.jpg" alt="IMG_1273.jpg" width="306" height="470"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/DSC_09385_1_94bb8c2579.jpeg" alt="DSC09385 (1).jpeg" width="4240" height="2384">

Boot Camp regarding Go-to-Market strategy for digital heathcare 

Paris, May 23th, 2024Future4care announces the signing of a new strategic partnership with TNP Consultants, European consulting firm specializing in strategic, operational, digital, and regulatory transformations for companies.Through this partnership, TNP will collaborate with existing partners (Havas Life Paris, Beys, IQVIA, Biocodex, UCB, Alira Health, FEHAP) in deploying innovative digital solutions for healthcare. In the context of a strong relationship with Future4care’s startups, pioneers in artificial intelligence and digital health, TNP Consultants will also contribute to exploring the economic models of tomorrow, particularly in the areas of prevention and the economy of aging.Agnès De Leersnyder, CEO of Future4care, says: “We are delighted to welcome TNP Consultants into our ecosystem. This new partnership fully aligns with our goal of bringing together the highest quality stakeholders to collectively accelerate progress in digital health in Europe, by fostering the emergence of global leaders in digital health through ideation, collaboration, and more broadly, innovation.”Benoit Ranini, President of TNP, declares: “We are pleased to formalize this partnership with Future4care, the European ecosystem for digital health, born from the collaboration of several international companies. This partnership aims to integrate TNP into the field of digital health innovation and highlights our ongoing commitment to technological progress. Through this alliance, TNP will participate in specialized training programs, contribute to significant events, and work jointly with the startups in the accelerator to contribute to the development of digital health in France, Europe, and internationally.”About Future4careFuture4care is a European ecosystem of multidisciplinary stakeholders dedicated to digital health. Joint Venture founded in 2021 by the alliance of <a target="_blank" rel="" href="https://www.capgemini.com/fr-fr/">Capgemini</a>,&nbsp;<a target="_blank" rel="" href="https://www.generali.com/">Generali</a>,&nbsp;<a target="_blank" rel="" href="https://www.orange.com/fr">Orange&nbsp;</a>et&nbsp;<a target="_blank" rel="" href="https://www.sanofi.fr/fr/">Sanofi&nbsp;</a>, Future4care brings together E-health players (large groups, experts, healthcare professionals, startups, etc.) to foster synergies and opportunities that will accelerate progress in digital health. Since its launch, Future4care has brought together seven industrial and institutional partners (<a target="_blank" rel="" href="https://alirahealth.com/">Alira Health</a>,&nbsp;<a target="_blank" rel="" href="https://www.be-ys.com/">Be-ys</a>,&nbsp;<a target="_blank" rel="" href="https://www.biocodex.fr/fr/">Biocodex</a>,&nbsp;<a target="_blank" rel="" href="https://havashealthandyou.com/">Havas Life,</a>&nbsp;<a target="_blank" rel="" href="https://www.iqvia.com/fr-fr/">IQVIA, </a><a target="_blank" rel="" href="https://www.ucb-france.fr/">UCB&nbsp;</a> and <a target="_blank" rel="" href="https://www.fehap.fr/">FEHAP</a>) and qualified personalities from the scientific and academic world within a Scientific and Ethical Comittee.About TNP ConsultantsFounded in 2007, TNP Consultants is a European consulting firm specializing in strategic, operational, digital, and regulatory transformations for companies.TNP operates in areas of operational strategy, information systems, business, and human capital, in sectors such as banking, insurance, transportation, energy, automotive, and the public sector. TNP has made accelerating the performance of its clients its DNA.Its teams are currently present in three geographical areas: Continental Europe (France, Luxembourg, Italy, Switzerland, Germany, Monaco), Africa (Morocco, Tunisia, Ivory Coast), Asia, and the Middle East (India, United Arab Emirates).

Future4Care and TNP Consultants Announce the Signing of a Partnership

The Serge Weinberg Trophies are a joint initiative of Future4care, a European ecosystem dedicated to digital healthcare, Foundation S-The Sanofi Collective and CentraleSupélec 21st, to reward the most innovative, high-impact digital solutions in line with the "One Health" approach to integrated healthcare. Entries for this first edition are open from March 29th until Saturday April&nbsp;27th.&nbsp;Faced with a complex context of demographic transition and climate change characterized by multiple health and environmental crises, it is becoming imperative to adopt an integrated vision of health.The "One Health" concept advocates an integrated approach to health, encompassing human, environmental and animal health.In this respect, the use of new technologies is particularly relevant to raising awareness and meeting the challenges of environmental health, helping to preserve biodiversity and improve the health of individuals and populations.The Serge Weinberg Trophies were created to promote and encourage high-impact projects in this field.&nbsp;At the end of the selection process, three prizes will be awarded:<ul><li>The Gold Trophy, worth €30,000,</li><li>The Silver Trophy, worth €20,000,</li><li>The Jury Prize, with one year's support from Future4care to the project.</li></ul>Projects can apply until April 27th, by sending their application to <a target="_blank" rel="" href="mailto:tropheesergeweinberg@future4care.com">tropheesergeweinberg@future4care.com</a>.For practical information and details of the Awards, click here.The jury will announce the 8 finalists on May 17th, and award the prizes to the three winners on Thursday June 27th at Future4care in Paris.<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/Logo_with_trophee_S_W_et_fond_b4fef149bc.png" alt="Logo with trophée S. W et fond.png" width="4000" height="4000"> &nbsp;The Serge Weinberg Awards juryJury chaired by Ms Chrysoula Zacharopoulou, French Secretary of State for Development, Francophonie and International Partnerships&nbsp;The Serge Weinberg Awards juryChrysoula Zacharopoulou - Secretary of State for Development, Francophonie and International Partnerships, FranceAbdelaali Elbadaoui - Social Entrepreneur | Founder of "Banlieues Santé" , "Banlieues School" , "Banlieues Climat" and "Café des Femmes", FranceJohanna Mair - Professor at Stanford University| Center on Philanthropy and Civil Society, USAKirsten Dunlop - CEO Climate KIC, European Innovation Institute, UK and NetherlandsJohn Dutton - Director UpLink and Member of the Executive Committee, The World Economic Forum, SwitzerlandRafaèle Tordjman - Founder and President, Jeito Capital Investment Fund, FranceYassine Laghzioui - Managing Director UM6P Ventures, University Mohammed VI Polytechnic, MoroccoStéphanie Hajjar - Director of Entrepreneurship and Innovation, CentraleSupelec, FranceVanina Laurent-Ledru - Managing Director, Foundation S - The Sanofi Collective, FranceAgnès de Leersnyder - Managing Director of Future4care, France&nbsp;About Future4careFuture4care is a European ecosystem of multidisciplinary players dedicated to digital health. A joint venture founded in 2021 by the alliance of <a target="_blank" rel="" href="https://www.orange.com/fr">Orange</a>,&nbsp;<a target="_blank" rel="" href="https://www.capgemini.com/fr-fr/">Capgemini</a>,&nbsp;<a target="_blank" rel="" href="https://www.sanofi.fr/fr/">Sanofi</a>&nbsp;and&nbsp;<a target="_blank" rel="" href="https://www.generaliglobalcorporate.com/">Generali</a>, Future4care brings together E-health players (major groups, experts, healthcare professionals startups, etc.) on a 6,500m2 campus to enable them to interact on a daily basis and create synergies and opportunities that will accelerate progress in digital health. Since its launch, Future4care has been joined by six industrial partners (<a target="_blank" rel="" href="https://www.biocodex.fr/fr/">Biocodex</a>,&nbsp;<a target="_blank" rel="" href="https://www.ucb-france.fr/">UCB</a>,&nbsp;<a target="_blank" rel="" href="https://www.iqvia.com/fr-fr/locations/france">IQVIA</a>,&nbsp;<a target="_blank" rel="" href="https://www.havashealthandyou.fr/">Havas Health &amp; You</a>,&nbsp;<a target="_blank" rel="" href="https://alirahealth.com/">Alira Health</a>&nbsp; and&nbsp;<a target="_blank" rel="" href="https://www.be-ys.com/">Be-ys</a>).&nbsp;About Foundation S-The Sanofi CollectiveThe philanthropic organization supported by Sanofi, has been working since May 2022 in four areas: the fight against childhood cancer, a historical commitment of Sanofi, emergency humanitarian aid, the eradication of tropical diseases and finally, a brand new field of action and THE major health challenge of today, the impact of global warming on health. To take effective action in these 4 areas, Foundation S - headed by Vanina Laurent-Ledru and chaired by Frédéric Oudéa- has adopted a methodology based on linking the global and the local, and encourages collective action through various forms of partnership, mobilizing the best experts, a think &amp; do tank...&nbsp;About 21st by CentraleSupélecAn impact gas pedal, 21st by CentraleSupélec supports students, researchers and entrepreneurs in the development of disruptive innovations and deeptech startups, from ideation to scale-up. As part of the entrepreneurial DNA of CentraleSupélec, which has been the source of numerous success stories in France and abroad, 21st by CentraleSupélec supports around a hundred projects/startups each year with a strong environmental and societal impact, in three areas of innovation: Climate &amp; Biodiversity, Health &amp; Care, Future of business. <a target="_blank" rel="" href="https://21st.centralesupelec.com/">https://21st.centralesupelec.com/</a>About CentraleSupélec: A leading higher education and research institution, CentraleSupélec has 4 campuses in France (Paris-Saclay, Metz, Rennes and Reims). It has over 5,000 students, including 3,800 engineering students, 400 teaching and research staff and 18 laboratories or research teams. CentraleSupélec is one of the world's leading institutions in engineering and systems sciences. Highly internationalized (25% of its students and nearly a quarter of its teaching staff are international), CentraleSupélec has forged over 170 partnerships with the world's leading institutions. The school is also a founding member of the Université Paris-Saclay.&nbsp;Press Contact Trophées Serge Weinberg: <a target="_blank" rel="" href="mailto:tropheesergeweinberg@future4care.com">tropheesergeweinberg@future4care.com</a>

"One health" digital technology for an integrated approach to healthcare. First Serge Weinberg Awards: applications open until April 27th

Future4care announces the launch of GenAI4care, an initiative dedicated to advancing Generative AI in the healthcare sector. Our ambition is to create a pioneering ecosystem in this field, bringing together major industrial groups, startups, researchers, academics and healthcare professionals on a European scale, in order to amplify the development of generative artificial intelligence use cases in healthcare.&nbsp;Agnès de Leersnyder, CEO of Future4care, commented: "Since its creation two years ago, Future4care has proved the effectiveness of its multidisciplinary approach. This new initiative is in line with our raison d'être, which is to bring together innovative players around the issues that will shape tomorrow's healthcare. Future4care was a pioneer in exploring Generative AI topics early on, and our ecosystem is now ready to accelerate the transformation of these forward-looking topics into concrete use cases at the service of patients and healthcare professionals."The deployment of GenAI4care is based on several major axes, some of which have already been initiated and will continue until at least 2025:<ul><li>The Accelerator will offer a call for applications from the Paris and Berlin campuses for startups developing Generative AI use cases in healthcare.</li><li>Through its Academy, the Institute will offer a training cycle in Generative AI in healthcare, as well as a think-tank dedicated to French and European competitiveness and to issues of data access and structuring.</li><li>The Innovation Factory, our co-development center, will work with ecosystem members on Generative AI use cases in healthcare.</li></ul>&nbsp;GenAI4care was launched at a Festival at Future4care on December 18th, 2023, which brought together the 4 founding CEOs of the ecosystem - Paul Hudson, CEO of Sanofi, Aiman Ezzat, CEO of Capgemini, Christel Heydemann, CEO of Orange Group and Jean-Laurent Granier, Chairman and CEO of Generali France. The event offered a holistic exploration of Generative AI in healthcare through four roundtables and a demonstration zone of use cases from ecosystem members.About Future4care:&nbsp;Future4care is a European ecosystem of multidisciplinary players dedicated to digital health. A joint venture founded in 2021 by the alliance of <a target="_blank" rel="" href="https://www.orange.com/fr">Orange</a>,&nbsp;<a target="_blank" rel="" href="https://www.capgemini.com/fr-fr/">Capgemini</a>,&nbsp;<a target="_blank" rel="" href="https://www.sanofi.fr/fr/">Sanofi</a>&nbsp;and&nbsp;<a target="_blank" rel="" href="https://www.generaliglobalcorporate.com/">Generali</a>, Future4care brings together E-health players (major groups, experts, healthcare professionals startups, etc.) on a 6,500m2 campus to enable them to interact on a daily basis and create synergies and opportunities that will accelerate progress in digital health. Since its launch, Future4care has been joined by six industrial partners (<a target="_blank" rel="" href="https://www.biocodex.fr/fr/">Biocodex</a>,&nbsp;<a target="_blank" rel="" href="https://www.ucb-france.fr/">UCB</a>,&nbsp;<a target="_blank" rel="" href="https://www.iqvia.com/fr-fr/locations/france">IQVIA</a>,&nbsp;<a target="_blank" rel="" href="https://www.havashealthandyou.fr/">Havas Health &amp; You</a>,&nbsp;<a target="_blank" rel="" href="https://alirahealth.com/">Alira Health</a>&nbsp; and&nbsp;<a target="_blank" rel="" href="https://www.be-ys.com/">Be-ys</a>).&nbsp;Press contact : Justine Spitzer –&nbsp;<a target="_blank" rel="" href="mailto:justine@future4care.com">justine@future4care.com</a>&nbsp;- 06 88 85 36 60

Future4care launches GenAI4care to accelerate Artificial Generative Intelligence in healthcare

Paris, July 3rd, 2023 - FEHAP, the leading federation of the solidarity-based private healthcare sector, and Future4care, the European ecosystem dedicated to accelerating progress in digital healthcare, have signed a partnership agreement aimed at combining their strengths to accelerate progress in digital healthcare.&nbsp;The flexibility and responsiveness of the private sector combined with the dynamism of e-health start-upsInnovation is at the heart of the concerns of FEHAP's member establishments and structures. The solidarity-based private sector is recognized for this. Proof of this is the wealth of projects honored each year at the Innovation Trophies. Under the drive of its new CEO, FEHAP is keen to go one step further by helping bring together the needs of its members and the solutions proposed by tomorrow's start-ups. This partnership will provide an opportunity for numerous meetings, exchanges, study sessions and joint projects.&nbsp;"Innovation whether technological, managerial or even in the service of ecological transition is at the crossroads of all the concerns of healthcare players. FEHAP is present in all fields, from cradle to grave. Healthcare players are well aware of the challenges of innovation. This is less obvious in the medico-social and social sectors. That's why we're counting on Future4care's support to bring innovative solutions to life for all our members, including those who have the least access to them", says Charles Guépratte, CEO of FEHAP.&nbsp;For its part, Future4care offers an acceleration program for start-ups in the 'E-health' field, with personalized support from a team of digital health experts. Future4care also comprises an Institute whose purpose is to support advances in digital healthcare and its adoption by healthcare professionals and patients alike. The Institute's reflections and actions take the form of a think tank, publications and events.&nbsp;"We're delighted that FEHAP is joining Future4care's partners. This partnership makes a lot of sense to us, as it is in line with our desire to bring together multidisciplinary players to discuss common issues, and that's what Future4care's mission is all about. I look forward to seeing the synergies and projects that will emerge from this partnership," explains Agnès de De Leersnyder, Managing Director of Future4care.&nbsp;About FEHAP :FEHAP, which has been active in all fields of social protection since 1936, brings together over 5,300 members, working within more than 1,500 managing organizations. These associations, foundations, congregations, mutual societies, supplementary retirement and provident organizations employ nearly 351,000 people, representing almost 12% of salaried jobs in the SSE sector. Its flexibility, combining private management and public service, places its establishments and services at the cutting edge of innovation and research. Its governance, drawn from civil society, is disinterested. As a result, all profits are reinvested in the facilities for the benefit of the people they care for.&nbsp; <a target="_blank" rel="" href="http://www.fehap.fr">www.fehap.fr</a>&nbsp;About Future4care:&nbsp;Future4care is a European ecosystem of multidisciplinary players dedicated to digital health. A joint venture founded in 2021 by the alliance of <a target="_blank" rel="" href="https://www.orange.com/fr">Orange</a>,&nbsp;<a target="_blank" rel="" href="https://www.capgemini.com/fr-fr/">Capgemini</a>,&nbsp;<a target="_blank" rel="" href="https://www.sanofi.fr/fr/">Sanofi</a>&nbsp;and&nbsp;<a target="_blank" rel="" href="https://www.generaliglobalcorporate.com/">Generali</a>, Future4care brings together E-health players (major groups, experts, healthcare professionals startups, etc.) on a 6,500m2 campus to enable them to interact on a daily basis and create synergies and opportunities that will accelerate progress in digital health. Since its launch, Future4care has been joined by six industrial partners (<a target="_blank" rel="" href="https://www.biocodex.fr/fr/">Biocodex</a>,&nbsp;<a target="_blank" rel="" href="https://www.ucb-france.fr/">UCB</a>,&nbsp;<a target="_blank" rel="" href="https://www.iqvia.com/fr-fr/locations/france">IQVIA</a>,&nbsp;<a target="_blank" rel="" href="https://www.havashealthandyou.fr/">Havas Health &amp; You</a>,&nbsp;<a target="_blank" rel="" href="https://alirahealth.com/">Alira Health</a>&nbsp; and&nbsp;<a target="_blank" rel="" href="https://www.be-ys.com/">Be-ys</a>).

FEHAP becomes a partner of Future4care, the European ecosystem dedicated to digital healthcare.

Paris and Berlin, June 22nd, 2023.&nbsp;Future4care, a European alliance of multi-sector players whose mission is to accelerate progress in digital healthcare, opens its business in Germany. This first opening of an international office is the concrete expression of the ambition that Future4care has pursued since its creation: bringing together healthcare and tech players on a European scale, and helping create synergies from which will emerge the digital healthcare leaders of tomorrow.&nbsp;&nbsp;Future4care's service offer for start-ups and partners will be available to the German market from September 2023. The first stage of this move to Germany was marked by a Future4care stand at the Bitz and Pretzels trade fair in Munich on June 20th and 21st, 2023, in collaboration with EIT Health.Future4care is already relying on the German subsidiaries of its partners and founders to launch its service offering and open facilities in Berlin.&nbsp;Future4care takes this opportunity to announce the appointment of Katherine Ossenkopp as Country Manager for Future4care Germany. Katherine Ossenkopp will be responsible for Future4care's strategy in Germany and for setting up the company.&nbsp;"We are living a unique moment to rethink our healthcare system with the contribution of technology. I'm convinced that we need a shared commitment to take this project forward. That's why I'm very excited to be joining Future4care and its strong multidisciplinary ecosystem in Europe, and I'll help establish impactful connections between Germany's leading digital healthcare players and beyond!" Katherine Ossenkopp comments.&nbsp;&nbsp;"I am delighted to welcome Katherine Ossenkopp. Her expertise in the German healthcare market, her mastery of digital healthcare and her leadership make her the ideal person to take on this new challenge, which marks an important milestone in Future4care's history. I'm looking forward to what we'll achieve together," comments Agnès De Leersnyder, CEO of Future4care.&nbsp;"The opening of Future4care in Germany is the first step in our European strategy. At Future4care, we are convinced that digital technology is the answer to modern healthcare challenges. A Europe-wide alliance of industrial partners will contribute to the overall success of the model. I'm delighted that Katherine Ossenkopp is joining us, and I'm sure she'll inject all the energy we need to achieve our goals." Explains Philippe Peyre, Chairman of Future4care.&nbsp;

Future4care opens its business in Germany, pursuing its ambition to be Europe's largest ecosystem of digital healthcare players.

19 new startups join the Future4care gas pedal

What prospects for mental health?

A successful international launch!

Future4care, one year at the heart of the e-health revolution

Paris, May 12th, 2022. UCB, an international biopharmaceutical company specialized and recognized in severe diseases in immunology and neurology, joins Future4care as a new member.Published on May 11th, 2022 at 06:59 a.m.The arrival of this Belgian biopharmaceutical pioneer, with more than 8,500 employees worldwide, reinforces the multidisciplinary approach sought by Future4care's founders.&nbsp;Joining Future4care illustrates UCB's commitment to proactive innovation. We share a common belief that we cannot solve the world's healthcare challenges alone, and that major breakthroughs will come from the use of new technologies and open collaboration. That's why the partnership approach is at the heart of UCB's drive to discover new tools, technologies and partners to connect with patients.Fabienne Delaplace-Lavoix, General Manager of UCB France explains that "UCB is extremely proud to join the Future4care community to accelerate the delivery of new healthcare solutions and meet new patient needs. It is by joining forces - dynamic companies, startups in Biotech and Medtech and the pharmaceutical industry - that we can unleash the power of innovation and, together, invent the future of our healthcare. Our mission is to create value for patients. And I think we've all understood that patient value calls on us to invent new possibilities."&nbsp;As a member of the Future4care Selection Committee, UCB will play a fundamental role in the ecosystem's governance, in order to :<ul><li>Define Future4care's annual themes and illustrations;</li><li>Participate in the choice of selection criteria for selected startups;</li><li>Help set the guidelines for the work of the Future4care Institute;</li><li>Contribute to the entry of new members.</li></ul>UCB will also take part in the selection of startups for the various calls for projects launched every six months.The new member will also benefit from access to the Future4care open innovation platform and a range of acculturation, collaboration and influence services.They will also be invited to contribute to the work of the Future4care Institute.For more information, visit <a target="_blank" rel="" href="https://future4care.com/fr">&nbsp;</a><a target="_blank" rel="" href="https://future4care.com">https://future4care.com</a>&nbsp;About Future4careFuture4care is the European e-health start-up gas pedal, born of an alliance between Capgemini, Generali, Orange and Sanofi. Its purpose is to accelerate the market launch of solutions capable of becoming European e-health champions. Future4care is a unique ecosystem in Europe:<ul><li>A 6400m2 space in the heart of Paris, in the 13th district, in the Biopark, to support start-ups in their acceleration phase;</li><li>An open innovation platform to facilitate acculturation, collaboration and influence within the community.</li><li>An Institute, a true knowledge center, offering programs and conferences related to digital health;</li><li>A benchmark label.</li></ul>&nbsp;&nbsp;About UCBAt UCB, our mission is never finished - because we always aspire to find new ways to develop solutions for people living with serious diseases. We act with determination to create value and make real improvements in the lives of the people we serve, now and in the future. We are guided by our commitment to people living with serious illness, who inspire our research and development in neurology, immunology and other areas where our expertise, innovation and ambition can address unmet needs. We build strong links with the patients and healthcare professionals who face these diseases every day, as well as with colleagues and partners who share our passion for tackling the challenges of severe disease.&nbsp;Press contact :Future4careVincent Puren<a target="_blank" rel="" href="mailto:vincent@future4care.com">vincent@future4care.com</a>&nbsp;UCB FranceFlore Houlet<a target="_blank" rel="" href="mailto:flore.houlet@ucb.com">flore.houlet@ucb.com</a>&nbsp;&nbsp;

UCB joins Future4care!

Paris, April 13th. Biocodex, a pioneer and major international player in the field of microbiota and women's health, joins Future4care as a new member.The arrival of this company, with over 1,600 employees, reinforces the multidisciplinary approach sought by Future4care's founders.Published on April 11th, 2022 at 10:15 amFor several years now, Biocodex has been investing in start-ups focusing on microbiota, its main area of expertise. The partnership with Future4Care, will enable it to accelerate in digital health and take its place in this ecosystem of excellence.Future4care and Biocodex share the same convictions, first and foremost that of bringing together the players in the ecosystem to make possible the innovations that will shape tomorrow's healthcare, for the benefit of the patient. By joining the initiative, Biocodex will contribute to the "factory" of solutions that address the issues of sovereignty over healthcare data on a European scale, and the question of how this data should be used.Nicolas Coudurier, CEO of Biocodex, comments: "We are very honored to be the first pharmaceutical industry partner chosen by the founders of Future4Care. Biocodex will contribute to the tremendous momentum created by this consortium in the service of tomorrow's healthcare. Our industry needs to forge links with players in the personal protection, digital and start-up sectors to address our new challenges, including societal ones, such as, beyond data, prevention. Biocodex is committed to its patients; Biocodex is also committed to its employees, who will benefit from the scheme proposed by Future4Care, which illustrates the acceleration in our transformation."As a member of the Future4care Selection Committee, Biocodex will play a fundamental role in the ecosystem's governance, in order to :<ul><li>Define Future4care's annual themes and illustrations;</li><li>Participate in the choice of selection criteria for selected startups;</li><li>Participate in setting the guidelines for the work of the Future4Care Institute;</li><li>Contribute to the entry of new members.</li><li>Biocodex will also take part in the selection of startups for the various calls for projects launched every six months.</li><li>New members will also benefit from access to Future4care's open innovation platform and a range of acculturation, collaboration and influence services.</li><li>They will also contribute to the work of the Future4care Institute.</li></ul>For further information, please visit : <a target="_blank" rel="" href="https://future4care.com">https://future4care.com</a>&nbsp;About Future4careFuture4care is the European e-health start-up gas pedal, born of an alliance between Capgemini, Generali, Orange and Sanofi. Its aim is to accelerate the market launch of solutions capable of becoming European e-health champions. Future4care is a unique ecosystem in Europe:<ul><li>A 6400m2 space in the heart of Paris, in the 13th district, in the Biopark, to support start-ups in their acceleration phase;</li><li>An open innovation platform to facilitate acculturation, collaboration and influence within the community.</li><li>An Institute, a true knowledge center, offering programs and conferences related to digital health;</li><li>A benchmark label.&nbsp;</li></ul>&nbsp;About BiocodexBiocodex is a French pharmaceutical company founded in 1953 around the development and marketing of the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745. Today, Biocodex is developing around three pillars: microbiota, women's health and orphan diseases.Biocodex employs over 1,600 people and achieved net sales of €418 million in 2021, of which 42% in France and 58% internationally. The Biocodex Group is present in 124 countries, including 20 through its own subsidiaries. Its products are distributed in the rest of the world by partner companies.&nbsp;Click <a target="_blank" rel="" href="https://youtu.be/a7vfoQXtQPc">here</a> to read the interview with Nicolas Coudurier, Managing Director of Biocodex.

Biocodex laboratories join Future4care!

On the occasion of the MedinTechs trade show, held in Paris on March 8 and 9, 2022, PariSanté Campus, a national program supported by the President of the Republic, @Hôtel-Dieu, supported by Assistance Publique-Hôpitaux de Paris, and Future4care, supported by Sanofi, Orange, Generali and Cap Gemini, are making public the unprecedented partnership they intend to enter into.Published on March 09th, 2022 at 01:00The digital revolution is a global transformation: it originates in research, is rooted in healthcare, and requires the deployment of industrial solutions that enable a change of scale in response to the expectations of patients and healthcare professionals, both in the city and in hospitals. To give France the best chance of playing a leading role in this revolution, it is essential to mobilize scientific, hospital-university and industrial forces, and to bring them together.This is the purpose of the partnership announced by the three major players - PariSanté Campus, Future4care and @Hôtel-Dieu - whose mission is to accelerate innovation in the healthcare sector, each with their own specific areas of expertise: PariSanté Campus in the field of research and training, Future4Care in the field of industry, and @Hôtel-Dieu in the field of university hospitals.By forging an ambitious partnership, these three players intend to bring together the ecosystems they form and lead to create a global digital health community. The goal of this partnership, which is open to all regions, is to increase France's national and international influence in this field.It includes a special focus on start-ups, which are at the heart of the digital health revolution. PariSanté Campus, Future4care and @Hôtel-Dieu, which offer differentiated and complementary services, have therefore joined forces to launch joint programs open to start-ups supported by the three initiatives.Four areas of collaboration are at the heart of this unprecedented partnership:<ul><li>To offer start-ups cross-support at the highest level, based on a group of six pilot start-ups expressing a strong need for articulation with the three worlds;</li><li>Offer a unique program of events, and thus become a hub of activity and exchange for a large global community of innovation in digital health, through joint events and coordinated programming;&nbsp;</li><li>Start collaborations around health data: lead joint reflection integrating the expectations and constraints of research, care and industry around health data, in order to accelerate the digital health revolution by identifying innovative strategies for sharing and analyzing data;</li><li>Coordinate the research efforts of the three structures, and propose joint publications between Future4care, Hôtel-Dieu and PariSanté Campus.</li></ul>More immediately, the three partners will be organizing cross-fertilization meetings with selected startups from the different structures:<ul><li>First, in April 2022, @Hôtel-Dieu will organize an initial hospital immersion day for start-ups and industry players;</li><li>Then, in May, Future4care will organize the first workshop with the 6 pilot start-ups;</li><li>Finally, in June, a workshop on health data will be held at PariSanté Campus.</li></ul>The purpose of this partnership is to provide the ecosystem with clarity and clear direction for digital healthcare startups. More extensively, the areas of collaboration identified will serve to make progress in digital healthcare as efficient as possible.Watch the official video of the partnership launch, <a target="_blank" rel="" href="https://youtu.be/wohfzR1phqM">here</a>.About PariSanté CampusPariSanté Campus is a campus for research, training, innovation and entrepreneurship in the field of digital health. It is made up of 5 founding members: the Institut national de la santé et de la recherche médicale (INSERM), the Université́ PSL (Paris Sciences &amp; Lettres), the Institut national de recherche en sciences et technologies du numérique (Inria), the Health Data Hub and the Agence du numérique en Santé (ANS). The aim of the PariSanté Campus is to structure an industry dedicated to digital health, with a global reach, and open to local, national and international partnerships. Through a center unique in the world, bringing together researchers, healthcare professionals, entrepreneurs, institutions and social players, PariSanté Campus will become the heart of tomorrow's healthcare.For further information: <a target="_blank" rel="" href="http://www.parisantecampus.fr/">www.parisantecampus.fr/</a>&nbsp;About Future4careFuture4care is a European gas pedal for e-health start-ups launched in January 2021, co-founded by four major European companies - Capgemini, Generali, Orange and Sanofi - united around the shared ambition of supporting start-ups as they scale up, to strengthen European health sovereignty and decompartmentalize interactions between healthcare system players. Future4care's mission is to accelerate the development of e-health solutions right through to market launch. Aimed at start-ups wishing to accelerate their transition to industrial scale, Future4care's range of services enables them to be housed in the Biopark building (6,400 m²) in the 13th district of Paris, and to benefit from tailor-made support combining access to knowledge and contacts with experts from our network. Future4care is also a forward-looking center for digital healthcare. Its reflections and actions will concern subjects linked to usage, ethics and both French and European economic sovereignty. The Future4care Institute will stand out for its highly expert positioning, its objectivity and its commitment to progress in digital healthcare. It will be guided by an interdisciplinary, scientific and ethical committee.For further information, please visit : <a target="_blank" rel="" href="https://future4care.com/fr">https://future4care.com/fr</a>About @Hôtel-Dieu@Hôtel-Dieu, supported by AP-HP and Université de Paris, is an initiative designed to accelerate innovation in healthcare, by enabling start-ups, healthcare professionals and researchers to work together in a new way at the heart of one of Europe's oldest hospitals. In the heart of the Hôtel-Dieu, and in direct contact with healthcare services, we are opening a support platform for start-ups, in partnership with BioLabs and the Digital Medical Hub, as well as a third-location facility which, in conjunction with research and healthcare, will enable us to work on the construction of new digital healthcare models. @Hôtel-Dieu has already enabled the launch of an initial project to build a universal remote patient monitoring platform with five leading start-ups: Lifen, Nouveal, Withings, Implicity and Nabla. The launch of @Hôtel-Dieu is in line with the actions undertaken by the AP-HP to accelerate innovation in healthcare, with the creation of the Carnot@AP-HP institute, the healthcare data warehouse and the Innovation Hub.

Future4care, @Hôtel-Dieu and PariSanté Campus announce ground-breaking partnership in digital healthcare

Today, Future4care would like to promote an important topic, which is being addressed and highlighted by our partner, Galen Growth.To mark International Women's Day, we'd like to promote the report 'Women's health in digital health', produced by Galen Growth.Published on March 04th, 2022 at 10:31 amAt Future4care, we wanted to know more, so we interviewed Sara Schmachtenberg, Head of Data and Analytics for Europe and the US, at Galen Growth.&nbsp;&nbsp;Here, we share the 5 key insights from this report and the key figures that emerge from it. At the end of this article, you will find the link to the full report, as well as a link to the full interview with Sara Schmachtenberg.&nbsp;&nbsp;&nbsp;<ol><li>Significance of women's health in digital health, for Galen Growth&nbsp;&nbsp;</li><li>State of business growth&nbsp;&nbsp;</li><li>Company financing&nbsp;&nbsp;</li><li>Solutions on the market&nbsp;&nbsp;</li><li>The market in the next few years&nbsp;&nbsp;</li></ol>&nbsp;Now, let's take these insights even further, with the help of a few key figures:&nbsp;&nbsp;<ul><li>Galen Growth's current definition of women's health includes: Obstetrics, women's oncology, women's sexual health, gynecology, women's fertility, hormonal health (including menopause).&nbsp;&nbsp;</li><li>The volume of global digital health companies focused on women's health is growing at a CAGR of 12% over 5 years, twice as fast as the overall digital health company growth of 6%.&nbsp;&nbsp;</li><li>Total funding for women's health-focused digital health companies in 2021 was $3.75 billion.&nbsp;&nbsp;</li><li>25% of women's health-focused digital health companies develop solutions in medical diagnostics, making them the leading group.  (Patient and wellness solutions occupy 2nd and 3rd place with 15% and 10%, respectively).&nbsp;&nbsp;</li><li>What's next? The growing maturity of companies and the abundance of venture capital will lead to an increasing number of acquisitions within women's health-focused digital health companies in 2022 and beyond.&nbsp;&nbsp;</li></ul>&nbsp;This report demonstrates the growing importance of women's health in digital health.&nbsp;&nbsp;At Future4care, we're keen to support initiatives like this, which is why we're supporting various startups dedicated to women's health in particular.&nbsp;Now we're looking forward to the next report.&nbsp;&nbsp;<a target="_blank" rel="" href="https://youtu.be/SIpzHeYmcaE">Here's</a> the link to the long version of the interview.&amp;&nbsp;More info and full report here:<a target="_blank" rel="" href="https://www.galengrowth.com/product/womens-health-global-digital-health-2021-thematic-report/">https://www.galengrowth.com/product/womens-health-global-digital-health-2021-thematic-report/</a>&nbsp;

How can digital technology improve women's health?

From lack of access to data, to being the last link in the chain, through fierce competition, there are many pitfalls for insurers in the healthcare environment.Published on February 24, 2022 at 09:11 amThese players, in association with the social security system, play a central role in patients' lives. In the digital age, they are more than ever determined on offering personalized support tailored to individual needs, as is already the case in many other sectors. The problem is that there's a big gap between will and reality. Once again, the lack of interoperability.To discuss this hot topic, we interviewed Yanick Philippon, Director of Group Insurance at Generali France.Care pathways: organization and playersStrictly speaking, there is no such thing as a universal care pathway between patient and insurer. However, we can build on what currently exists via the Generali France customer area and its corollary, the mobile application. Today, the patient interacts with his or her complementary health insurance provider prior to treatment, for example to submit a quote, a request for reimbursement or to seek a second medical opinion before undergoing treatment or an operation. Then, once the treatment has been carried out, the patient receives the reimbursements to which he or she is entitled as a policyholder.Between these two phases, however, the insurer has no information about the patient's care path. This is the prerogative of the Caisse Primaire d'Assurance Maladie (local sickness insurance fund, "CPAM"). This information is then transmitted to the Dossier Médical Partagé (shared medical file, "DMP"), a digital health record that stores and secures the patient's health information: treatments received over the last 12 months, medical history (pathologies, allergies), test results, hospitalization reports, etc. The only people who have access to this data are the attending physician and all healthcare professionals (except occupational medicine), including hospitals.Since January 2022, existing DMPs have been migrated to a new platform called "Mon Espace Santé" (My Health Space), where new files will also be created. Until March 2022, all Social Security subscribers will be notified and will be able (if they so wish) to refuse the activation or creation of their space."Mon Espace Santé" has two main functions. First, to become one's own medical file. This will enable you to store medical documents added by you or your healthcare professionals. It will also allow you to add documents and information that predate the creation of this space, in order to retrace your medical history. In short, the paper health record we've treasured for years is going digital.The second feature is instant messaging. As patients, we can exchange or receive information or documents from our healthcare professionals.Reassurance and trust for better supportThe constraints faced by players such as Generali, through its complementary healthcare offering, are not a new issue. Patient medical data is completely sealed off from institutional players. As the CPAM states on its public information website: "Neither the occupational health service, nor mutual insurance companies, nor banks, nor your employer can access your Dossier Médical Partagé (shared medical file). Finally, any access to your DMP by an unauthorized healthcare professional would constitute an offence punishable by imprisonment and a fine".This is a constraint considering these players could better support their policyholders if they had access to some of this information. Knowing a patient's pathology, for example, makes it easier to provide specific advice on pricing without compromising the quality of care and treatment.For some treatments, variations in the fees charged can be of a magnitude that is not always justified. The same applies to prescription drugs. Wider access would make it possible to offer more precise, better-adapted health cover for the patient.Since January 1, 2022, with the opening of "Mon Espace Santé" (My Health Space), every person affiliated to the general Social Security scheme has been able to grant or restrict access to their DMP. However, this only applies to healthcare professionals. For example, a chiropodist will not be able to access your hospital reports.Another obstacle is the patient's reluctance to share his health data with his insurer. While this is absolutely not the case on the part of the insurer, there is nevertheless a fear of being selected and somehow penalized by more expensive rates, or even of being cancelled or refused complementary health cover. There is undoubtedly also confusion with the loan insurance process, where each person must fill in a health questionnaire on their honour, and may have to undergo some medical tests.Clearly, we must continue to reassure patients that there is no intention to discriminate.Likewise, there is an ongoing need for in-depth educational work to show the real added value for the patient of sharing certain data. In the case of the second medical opinion to which a patient is entitled through his or her complementary health insurance, having more data would enable a more refined diagnosis or medical advice to be given for the benefit of the patient. The more data is available to understand the patient's care pathway, the more efficient the services offered will be.Even more so, it's the ease with which data can be made available and used that is essential if patients are to benefit from the best possible prevention, the best possible care pathways when medical intervention is required, and the best possible post-intervention follow-up. In this respect, a digital health innovation ecosystem such as Future4care represents a tremendous opportunity to accelerate the development and marketing of e-health solutions based precisely on data, to the benefit of all, in particular patients and healthcare professionals.The divide between players has a direct impact on patientsThere is no denying that strong reluctance exists and persists at various levels of the value chain. For healthcare professionals, extending access to health data is very often seen as a form of increased control over their medical acts by non-legitimate third parties, or even a stronger possibility of questioning and contesting their diagnoses. Here, also, there is a need for explanation and dialogue in order to gradually overcome resistance and apprehension, and move towards mutual cooperation in the service and benefit of the patient.L’Etat lui-même n’est pas toujours exempt de certaines frictions. Le rapport du Haut Conseil pour l’avenir de l’assurance The State itself is not always exempt from certain frictions. The report by the Haut Conseil pour l'avenir de l'assurance maladie (HCAAM) on the "Grande Sécu" project (commissioned by the French Ministry of Health) is a prime example. At the moment, four scenarios for linking basic compulsory health cover to supplementary health cover are being studied. From the most radical to the most "balanced", these 4 hypotheses would de facto lead to the nationalization of health coverage and the marginalization of supplementary health insurance.If this project were to see the light of day, it would undoubtedly create a profoundly unfair system, creating a divide between those who can afford to pay more without public support and gain rapid access to the best professionals, and those who cannot.Such a scenario does not correspond to the expectations of healthcare professionals, and above all to the expectations of the French in general, who are deeply attached to a certain freedom of activity and choice.There are still things that can be done to improve health coverage for the population, in particular the most vulnerable, but this "Grande Sécu" scenario is clearly not the right decision to take. Common sense must prevail on this issue.Digital health care, the key assetThe subject of the "Grande Sécu" is divisive, while the benefits of digital technology are increasingly unifying the thinking of our ecosystem. In fact, it's difficult to be totally exhaustive about the qualities of digital technology, given the number of positive contributions it can make to a patient's healthcare pathway at any given stage. Connected devices, for example, are a formidable lever for optimized, personalized daily monitoring of various chronic diseases such as cardiac arrhythmia, asthma and diabetes, as well as for post-operative monitoring on an outpatient basis and/or at home, rather than in hospital for longer periods.Prevention is another fundamental area where immense progress can be made thanks to digital technology, for a better understanding of the patient's lifestyle and environment.For healthcare professionals (as well as for governments and insurers), predictive medicine also opens up a vast field of opportunities, such as better anticipating and curbing the onset of certain pandemics or more familiar epidemics like influenza, gastroenteritis and seasonal allergies. With the launch of messenger RNA vaccines against Covid-19, for example, the world has become aware of the fantastic progress made by digital RNA sequencing and synthesis technologies. This technology also opens up great prospects for information storage, with capacities never achieved before .The challenge of telemedicineIt's impossible to talk about digital technology without mentioning the long-standing subject of telemedicine. To be functional, telemedicine requires sufficiently powerful infrastructures and telecommunications networks. 20 years ago, access to fiber optics and mobile broadband was still in its infancy in terms of deployment across France.Today, fiber and 5G have a much higher coverage rate, although there are still white zones where patients and healthcare professionals cannot use telemedicine. As a result, the use of telemedicine will be facilitated and amplified.Furthermore, beyond the question of infrastructure, we need to encourage the use of remote healthcare services as soon as possible. In this respect, a very interesting step forward was taken on January 27. The French National Authority for Health (HAS) published four guidelines to help healthcare professionals make the most of remote medical monitoring. These guides define the conditions for prescribing telemonitoring, the minimum technical specifications required for digital medical devices and collection accessories, the conditions of distribution and use, the professionals involved, the professional qualifications required, the organization of telemonitoring, the minimum provisions necessary to ensure quality of care, and the follow-up and use of telemonitoring.By July 1, reimbursement for remote medical monitoring will be generalized for several pathologies (diabetes, renal failure, heart failure and chronic respiratory disease). In the near future, patients with implantable cardiac prostheses will also be covered. For healthcare professionals, this means they can remotely interpret data for their patient's medical follow-up, and even adapt their treatment. This remote monitoring can detect a worsening in a patient's state of health, enabling them to intervene more rapidly. These devices are real assets in demonstrating the immense benefits of digital technology in healthcare.Future4care, catalyst and gas pedal of progress in digital healthcareFuture4care has a fundamental role to play in this digital health ecosystem. This is what led Generali to become one of the four founding partners (alongside Sanofi, Orange and Capgemini) of this innovative and powerful initiative, which will help to model the healthcare of the future and find new technological solutions and innovative services for patients. The insurance industry works statistically with a large volume of anonymized data and a history spanning several decades, which can be made available to startups to fuel their search for solutions.In the teeming world of startups, Future4care acts as a veritable catalyst, identifying the most relevant and promising digital healthcare projects, supporting them to accelerate their development and bring them to market for the benefit of healthcare professionals and patients alike.Secondly, Future4care is a physical and virtual forum for exchange and technology watch, which will forge closer links between major players such as the four founders involved in digital health, start-ups who will be able to test, make reliable and launch concrete, innovative solutions, and players from the medical world, universities and patient associations. The idea is really to build more bridges between these communities, all of whom are ultimately working towards the same ultimate goal: better prevention to better protect everyone's health, and better care to better restore quality of life.

Insurers, patients and health data

This week, Future4care is featured in Les Echos, in an article by our Vice-President Olivier Guerin. He discusses the central role of healthcare professionals in the digital transformation of the healthcare system.Published on February 15, 2022 at 10:23 amAt Future4care, we're convinced that digital healthcare offers considerable potential for improving care, both in terms of performance and human quality. This is what we wanted to express with our Vice President Olivier Guerin, who is also a doctor.Doctors remain essential in this new paradigm, but their role and the way they work are changing. This should not frighten them. The anxiety generated by digital tools is more a problem of ego than ethics.This leap of scale will give the healthcare system the breathing space it needs, and the professional fulfillment it so sorely lacks.The article is available online at <a target="_blank" rel="" href="https://www.lesechos.fr/idees-debats/cercle/opinion-accelerons-le-sante-le-numerique-sauve-des-vies-1386580">Les Echos</a>&nbsp;Echos and below.

Digital technology can save our healthcare system

The Future4care team had the opportunity to exchange with Dr Rafaèle Tordjman, founder of the investment fund Jeito.Published on January 12th, 2022, at 08:50 AMA video interview to discover at the end of this article. 5 key facts Dr. Rafaèle Tordjman :&nbsp;<ol><li>Rafaèle Tordjman is a Hemato-Oncology physician and scientist by training, with a PhD in Molecular Biology and Immunology.</li><li>Drawing on this experience, Dr. Tordjman has been investing in biotech for over 20 years, and has sat on the boards of some of its companies. These investments have generated five approved products and around 20 drugs in late-stage clinical development.</li><li>In 2018, Dr. Tordjman founded Jeito Capital, an independent investment company dedicated to biotech, to establish a continuous funding model and invest in the next generation of leaders in medical innovation. Her ambition is driven by a deep knowledge of the healthcare sector, and of biotech in particular. In creating this fund, Dr. Tordjman has once again demonstrated the importance of collaboration between the various players in the healthcare sector. Jeito raised 534 million euros ($630 million) in September 2021, becoming Europe's largest independent life sciences fund. </li><li>In July 2021, Dr. Tordjman was appointed by French President Emmanuel Macron to promote the French biotech ecosystem to major international players. Her mission is to attract healthcare and medical innovation talent to the French ecosystem. &nbsp;</li><li>Dr. Tordjman supports Future4care in its vocation to bring the ecosystem together to create a more cohesive healthcare system, with a view to the emergence of tomorrow's e-health solutions. "What is still to improve is how to work together, within an ecosystem, instead of working by silo. [...] It's exactly what Future4care wants to do".&nbsp;&nbsp;</li></ol>At Future4care, we're convinced that initiatives like Jeito will help make our healthcare system robust and sustainable. Our vocation is to federate them as a trusted third party to accelerate progress in digital healthcare. Discover the full<a target="_blank" rel="" href="https://youtu.be/mAn7EvkI-D8"> interview</a>&nbsp;of Docteur Rafaèle Tordjman.&nbsp;

Meeting Rafaèle Tordjman from the investment fund Jeito

Paris, January 6, 2022- be ys, the expert in high-tech digital trust and data governance applied to insurance and healthcare, becomes Future4care's first industrial member.Published on January 06th, 2022 at 09:54 amThis collaboration expands the Future4care ecosystem to support and accelerate the development of French and European start-ups offering digital health solutions. be ys is a service management technology platform for numerous players in the Insurance, Healthcare and Personal Protection sectors. The company develops differentiating services from a position of absolute neutrality and integrity, protecting its customers' data assets at the cutting edge of today's technologies. be ys is also involved in crucial areas concerning digital health, such as secure payments and transactions with patients, the sovereign cloud, and the processing and hosting of sensitive and personal data in highly secure data centers. The be ys group currently employs 3,200 people worldwide, 460 of whom are based in France. As a member of the Selection Committee, be ys will play a fundamental role in the governance of the ecosystem, in order to :&nbsp;<ul><li>Define Future4care's annual themes and sub-themes;</li><li>Participate in the choice of selection criteria for selected startups;</li><li>Participate in setting the guidelines for the Institute's work;</li><li>Validate the entry of new members.</li></ul>be ys also participates in the selection of startups for integration into the ecosystem, during "Calls for projects", benefits from access to Future4care's open innovation platform and a range of dedicated services (workshops, demo days, reverse pitching, training courses), and finally, contributes to the work of the Institute and the Future4care Think Tank.&nbsp; Future4care's ambition is to federate all healthcare players (patients, healthcare structures, start-ups, academics and institutions, public and private) in order to collectively invent the future of e-health and make Europe a key player on the world stage, guaranteeing its sovereignty in this field.&nbsp; With this in mind, in 2022 Future4care will inaugurate a unique venue in the 13th district of Paris, to bring together selected start-ups, representatives of members and a community of experts from the acceleration program, to foster collaboration while preserving confidentiality. The various stakeholders will also have the opportunity to capitalize on the new solutions provided: proposing and/or participating in the co-development of innovative solutions.For more information, visit <a target="_blank" rel="" href="https://future4care.com/fr">https://future4care.com/fr</a>About Future4careFuture4care is the European gas pedal for digital healthcare start-ups, born of an alliance between Capgemini, Generali, Orange and Sanofi. Its aim is to accelerate the time-to-market for innovative, real-world e-health solutions. Future4care is a unique ecosystem:&nbsp;&nbsp;<ul><li>A 6400m2 space in the Biopark in the heart of Paris, in the 13th district, to support startups in their acceleration phase;&nbsp;</li><li>An Institute, a true knowledge center, offering programs and conferences related to digital health;</li><li>A benchmark label.&nbsp;&nbsp;</li></ul>About be ysbe ys is an international group specializing in digital identity, personal information flows, and the processing and hosting of sensitive data. We create and monitor digital solutions in the processing of sensitive data in demanding business sectors such as health, security, payments, rights, sensitive transactions... Our products are designed according to a by-design security principle that guarantees compliance with all legal and regulatory requirements (such as the RGPD). As a national leader in data governance, we deploy these solutions using cutting-edge technologies.&nbsp;&nbsp;

Future4care, Europe's leading gas pedal for digital healthcare startups, announces the arrival of be ys as its first member partner

In just two years, digital technology has accelerated a process that would certainly have taken much longer without the epidemic. Go a few months back and remember how you used to get to a doctor. The transformation is radical for patients and healthcare professionals, and even more so for governments.Published on December 20th, 2021 at 04:51 amTaking stock, Europe notes the stranglehold has tightened even further, with China to the East and the United States to the West. The new era is being ushered in by this Sino-American duopoly led by their famous GAFAM and BATX. This geopolitical situation raises the question of strengthening Europe's impact and sovereignty.&nbsp;If the epidemic precipitated this mutation, it has also accelerated European decisions in favor of the EU's digital and health sovereignty. To tackle this subject in all seriousness, we wanted to call on a person who is versed in economic as well as geopolitical issues linked to healthcare, with a strong affinity for the digital world. That is why we spoke to Sanofi's Director of Public and Government Affairs, Clotilde Jolivet.<img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/Capture_d_ecran_2024_07_31_191955_2b0977d707.png" alt="Capture d'écran 2024-07-31 191955.png" width="1215" height="715"> &nbsp;Digital technology at the heart of Europe's transformationThe crisis has made most people aware of the importance of achieving a high level of autonomy for essential and innovative products, whether medicines or technologies, a challenge that the healthcare industry has been addressing for years. In both cases, digital technology plays a central role, transforming our entire industry. This quest is that of e-health sovereignty. E-health will play an increasingly central role in the provision of healthcare, as well as in the organization of the healthcare system. The supply, organization and development of treatments must be thought out on a European scale, otherwise we will not be able to establish our own sovereignty.This is vital, not only for the production of goods, but also for the creation of value in the short, medium and long term. It's a matter of reconquest, since we have too quickly left this subject in the hands of other geographical plates. Digital technology is still in its infancy, and could well be our best ally in this reconquest.We need to move swiftly from aspiration to operation, and organize on a European scale with a clear, easily deployable roadmap.Health data as the driving force behind e-sovereigntyIn the West, as well as in the East, the ideology is relatively different from that of Europe. The European Union, the world's third-largest economic power, is still struggling to position itself as the instigator and federator of European e-health. Notably because there are still major disparities between member states.Digital technology creates value and is an opportunity for economic growth, job creation and attracting investors and talent.Faced with the temptation to turn to solutions originating from North America or China, Europe must give itself the means to create real conditions for the deployment and massive use of healthcare data, by research teams, start-ups and industrialists, and resolve the ecosystem's challenges when it comes to using this data: facilitating the identification of sources and pooling them, providing for European data storage, establishing interoperability, avoiding the multiplicity of national legislations, guaranteeing the valorization of this data by regulatory and assessment authorities, ...Data protection is another interesting example. Europe was a forerunner with the RGPD, and showed citizens that protecting their data was important. We therefore have a secure framework to develop innovation on health data and health solutions. China is in the process of strengthening its legislation, which allows the state to access all data generated on its territory, under the banner of national security, and without any guarantee of protection of either personal data or intellectual property. Europe can therefore assert itself as an attractive and competitive region in comparison to the USA.To achieve this, European institutions need to harmonize and pool their approaches. In other words, they must fight against a heterogeneous vision among its 27 members, and avoid repeating the same mistakes made in the past decades with regards to medicines. Europe has a multitude of approaches specific to each country, making it difficult, until now, to produce and distribute on the same scale,In 2022, if we want to be attractive and successful, we need to help our European start-ups avoid an uphill battle for evaluation and market access, so that they can develop rapidly in our market, then expand and move to the USA or elsewhere. Because the reality today is that some of our most ambitious entrepreneurs think first of the market across the Atlantic, even before establishing themselves in Europe. Fund-raising is easier and faster in the US because the market is unified, and the launch of a healthcare solution takes place de facto in a vast, harmonized market. We need to guarantee them a secure, interoperable and harmonized space.&nbsp;In the short term, the European Union must take three steps in particular:<ul><li>Propose harmonized regulations throughout Europe to guarantee simplified, secure deployment of healthcare data, which is the area of innovation par excellence for start-ups.</li><li>Guarantee European markets to encourage the emergence and industrialization of our future champions, first on our own territory, before exporting them.</li><li>Interconnect the dozens of European data initiatives, such as the Health Data Hub in France. These initiatives, however brilliant, will only be of limited interest in the medium term if they are not interoperable. At least if we wish to guarantee a market large enough and solid enough to compete with the East and West.</li></ul>&nbsp;Evaluate to guarantee reliable industrialization over the long termObviously, going fast and offering a clear, predictable framework is only a short-term advantage. In e-health, more than anywhere else, this is not a sprint, but a marathon. A key challenge in creating value in e-health is evaluation. It is essential to guarantee safety and efficacy, whether through CE marking for medical devices or, of course, clinical trials for drugs. We still need to find the right evaluation model for digital health products and services.This logic must obviously remain demanding for the good of patients, without becoming counter-productive, and it must be thought out on a European scale. Once an e-health start-up has validated its technology, it should be able to deploy it rapidly, rather than knocking on 27 assessment agency doors. Research and development work is already risky, so we need to make the evaluation stages as easy as possible, and support our entrepreneurs before they go to market.This does not mean reimbursing all devices and solutions, but rather formalizing and harmonizing approaches and methodologies, for example to measure the impact of solutions that generate efficiency gains in healthcare. In short, we need to move towards more co-construction, and put real resources in front of entrepreneurs...Co-investing in risk with entrepreneursDigital reconquest in Europe's healthcare sector is also a question of multidisciplinarity. The relationship between the private and public sectors, on a local scale and even more so on a European scale, is perceived as a power struggle linked to structural and cultural differences. Yet they are interdependent. The role of public authorities is to ensure that the framework in which we evolve is appropriate. At the same time, private players – whether they are manufacturers, investors or entrepreneurs - play an initiating role. The former need solutions that respond to the problems encountered by citizens, while the latter need favorable regulations and the capital to design and deploy them.Today, however, it's difficult to obtain financing when there's a risk involved (regulatory, but not only). That is what's holding back the rise of our start-up ecosystem. It is in their nature to take risks, and we need them to innovate. The same applies to manufacturers.&nbsp;&nbsp;There is a whole acculturation process to be thought through around this notion.Today, we have a logic centered around subsidies (research tax credits, etc.), but no logic of co-investment in national and European risk. In the USA, the crisis has highlighted the role of the BARDA agency, which has invested massively in vaccine research, but which existed long before the crisis and whose role is to co-finance risk with private companies, whether in R&amp;D or industrial deployment. The co-financing of risk is one of the strong points that will enable Europe to find its identity and achieve health sovereignty. We have been able to do this in the field of defense, in a regal logic, since the public authorities do not question the vitality of defense. The creation of the future HERA agency, and its industrial arm Eu-FAB, is a step in the right direction, but we need to speed up its creation and operationalization, so that projects by start-ups and larger companies can be boosted and anchored in Europe.It's all about risk. The bigger the risk, the bigger the companies resulting from it wil be.A clear framework for risk-taking is what will set us apart from other geographies, and attract talents capable of thinking up solutions. They need to have confidence that risk-taking is part of our culture.&nbsp;Banking on multidisciplinarityBeyond taking risks, consolidating a unified vision of healthcare data will undoubtedly be key to regaining a central geography. Of course, not all European Union countries are committed in the same way or at the same pace. Moving forward together means accepting that we have to deal with each other's differences. With its Presidency of the EU in the first half of 2022, France is in a position to make progress in the field of health data.<ul><li>Defining the rules of the game and interoperability. In other words, creating a secure, easily accessible and value-creating structure.</li><li>Including the citizen. Helping them understand that the challenge is not to track data, but to create value for them, for their health, for progress, and so on. And to make them contributors to this new system.</li><li>Helping patient associations. These key players have understood, particularly in the case of rare diseases, that registers and monitoring are needed to save time and win the race against time in the face of these diseases.&nbsp;</li><li>Reducing inequalities. Sharing data will enable us to rationalize our healthcare system and help every citizen benefit from a personalized, and therefore fairer, system.</li><li>Preventing future crises. Data will guarantee the resilience of the healthcare system, thanks in particular to its predictive promises.</li></ul>What's certain is that we can't achieve these goals without multidisciplinarity and risk-taking. We need open institutions, ambitious entrepreneurs, agile industrialists and, more broadly, a resolutely positive ecosystem at the service of European-style sovereignty.&nbsp;&nbsp;

For e-sovereignty in healthcare!

Future4care's raison d'être is to guarantee its entrepreneurs and members access to a multidisciplinary network. That's why we're keen on surrounding ourselves and forge partnerships with the best in their field. Today we are pleased to announce that Digital Pharma Lab, a gas pedal of PharmaTech solutions, is joining the Future4care ecosystem.Published on December 17th, 2021 at 09:53 amThis PharmaTech solutions gas pedal joins Future4care, along with the other players in the ecosystem, to accelerate progress in digital healthcare together.&nbsp;This partnership promises to be exciting and unifying. The alliance between our two structures is in line with our desire to be a necessary and competent lever for entrepreneurs and manufacturers, but also to be a natural link between all the stakeholders who make up our rich healthcare system.&nbsp;What are the main thrusts of this partnership?&nbsp;It goes without saying that we are convinced that digital healthcare represents the future of our system. To this end, we at Future4care are developing an acceleration program for start-ups that already have the vision, but need the keys to open the right doors. We are also setting up an institute to accelerate the acculturation and transformation of large companies. With Digital Pharma Lab, we are convinced of the need to raise awareness even before providing support. That is why our partner, Institut Mines-Télécom Business School, is launching an executive master's degree focusing on "digital innovation in healthcare". Naturally, it was decided that this master's degree would be housed on the Future4care campus, in the 13th district of Paris.&nbsp;In addition, the healthcare system, like the digital one, is in a state of flux, constantly renewing itself. It is essential that the players in this system are able to take advantage of these changes. This is why members of our ecosystem will be taking part in acculturation modules offered by Digital Pharma Lab experts, and vice versa.&nbsp;Both organizations bring together a large number of skilled and influential experts. It's important that all the other players in this system can benefit from such knowledge and expertise. This is why we will be jointly offering masterclasses, training courses and workshops on specific themes.&nbsp;This partnership is also, and above all, an opportunity for both ecosystems to advance towards a common goal: supporting the development of tomorrow's healthcare solutions.&nbsp;More informal exchanges between our two communities will be set up to create meetings, synergies and even collaborations. This is why the Digital Pharma Lab teams will have offices on our campus, close to start-ups, manufacturers and all Future4care stakeholders.&nbsp;Click <a target="_blank" rel="" href="https://youtu.be/yHHu6LQxzVw">here</a> for the full interview with Pascal Becache, co-founder and Director of Business Development at Digital Pharma Lab.

Digital Pharma Lab joins the Future4care ecosystem

In the field for many years, close to patients and healthcare professionals, our Vice President, Olivier Guerin, shares his view of current #eHealth challenges.Published on December 13th, 2021 at 08:52 amAll players in the healthcare system agree that it's time to change things. It's time for a more preventive and predictive system. It's time for professionals to be better equipped to prevent new pandemics, time for patients to easily find a specialist whatever the context, time to be diagnosed sooner, faster. &nbsp;The recent pandemic has revealed the shortcomings of a healthcare system that was once avant-garde, but is now failing to transform itself. Yet this system is made up of strong players, expert and dedicated professionals, and committed public and private organizations. At the same time, there are powerful levers that, used in the right way, can support these players in this transformation. These include, of course, digital technology and all the tools that go with it.Professor Olivier Guérin, a member of the French President's Scientific Advisory Board and Vice-Chairman of Future4care, shares his vision of these ongoing changes and explains how digital technology can be used to initiate them.<img src="file:///C:/Users/CHARLO~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" width="1" height="1"><img src="https://f4c-strapi.s3.gra.io.cloud.ovh.net/Capture_d_ecran_2024_07_31_193341_c7c6a0d77f.png" alt="Capture d'écran 2024-07-31 193341.png" width="859" height="633">&nbsp;N°1 - Focus on the <a target="_blank" rel="" href="https://youtu.be/FJLBqEvAYhA">patient</a>, a player at the heart of the system.For Olivier Guérin, in healthcare, the patient is the keystone of his or her own care. In e-health, this is all the more important as patients must not only agree with the devices - since information is always being shared - but also play an active role in their own devices, in terms of their autonomy and the way in which they view their health, and share their health data with all professionals in the sector.It is essential that both patients and healthcare professionals are aware of the need to move forward in a spirit of co-construction and innovation. That is why all the players in the healthcare system need to show patients what can be done today, thanks to digital tools, and support them in their use.So it is important to remember why digital technology will improve the patient experience.This data is the key to more effective, more personalized treatment, provided that patients retain control over their own data.That is why they must realize that this health data belongs to them. The ability to share their data and understand how their treatment is structured with the help of digital tools will give them greater comfort. What's more, healthcare professionals are there to support and advise them. And it is all the easier when digital tools are at their service to simplify this support.That said, there is still an important issue to be addressed: making e-health inclusive.Indeed, the state of health tends to deteriorate, particularly when advancing in age, which is a risk factor, especially for chronic diseases. And it's this more vulnerable target group that we need to focus our efforts on if we are to help.It is essential to step up training, adoption and dissemination to these more vulnerable populations of the tools they need to manage their own health. And it's the job of healthcare professionals to democratize these devices, to explain, inform and train patients themselves in the use of these useful tools.&nbsp;N°2 <a target="_blank" rel="" href="https://youtu.be/N2TVUbOlyU0">Healthcare professionals</a>, also, need to take the plunge and embrace digital technologyOf course, there's no such thing as a healthcare system without professionals. In the current system, the attending physician is a keystone, since he or she is the integrator of all health data for the patient.However, as time goes by and public health needs change, we realize that it is a succession of players in the healthcare system who are effective for the patient.Thus, the players in the healthcare system in the broadest sense are obviously the professionals who must act, but who must act in a coordinated way.What better way to coordinate than, in particular, with digital solutions and products that enable this very specific exercise of patient care and its coordination.However, digital tools by doctors, and GPs in particular, are currently regarded as gadgets. How come?Because the French healthcare system was built on a succession of therapeutic acts. That is why we pay for consultations.But public health needs have changed, notably with the chronicization of illnesses, so we also need to change the way we, as healthcare professionals, see the service we provide to patients. This requires us to work differently, and to do so we need different tools, which is what digital innovation is all about.We need to be able to analyze all the data we need, or at least to have the tools that enable us to draw signals from it, so as to be constantly vigilant. This will enable us to avoid the so-called decompensations of chronic diseases, which are at the root of the deterioration in our fellow citizens' state of health, when treatment is not up to scratch. In the end, it's a great opportunity, but it also changes our vision and practices.Digital tools in the healthcare sector frighten health professionals, or generate anxiety, quite simply because they force us to work differently.However, we have chosen our professions because we want the best for our patients. This conviction is shared by all healthcare professionals.&nbsp;It's up to us, as professionals, to take up organizational issues and say to our supervisory bodies: "Ultimately, the model you're putting us into - these stories of one-off consultations paid for one after the other, for example - doesn't suit us. It doesn't suit us, because it forces us not to do our job properly. And that, for us, is unbearable."Basically, when a tool allows us to do better, we end up adopting it.&nbsp;&nbsp;N°3 Digital technology to unite <a target="_blank" rel="" href="https://youtu.be/oLc211kc53U">private and public players</a>The healthcare ecosystem is quite complex, since it includes not only healthcare professionals, but also - and this is what Future4care is all about - manufacturers capable of bringing us new solutions. And let's not forget other players, too often in the shadows, such as local authorities. In particular, town halls, departments and regions. These are key players when it comes to economic development and, in particular, prevention. There is also a French specificity. Patient associations. They are essential players to include in this ecosystem, because they have the extremely detailed knowledge we need. Generating innovation without them is virtually impossible.&nbsp;Having said that, it is well known that there's a long-standing French opposition between these private and public players.&nbsp;The presence of a professor and doctor as Vice-President of Future4care is not insignificant. It's also to make the link between these two types of players, whether in healthcare or industry.&nbsp;&nbsp;The aim of this rapprochement is, quite simply, to be of service to patients. As soon as this objective is shared, there is no longer any boundary between the private and the public sectors, as long as the necessary safeguards are put in place, in terms of respect for the patient, respect for patient confidentiality and respect for the patient's person and autonomy. We all need to be on board.That's how we will live up to the expectations of our fellow citizens and ourselves, as potential future patients.However, it is clear that there is fragmentation, due to this ancestral opposition. This fragmentation in the healthcare system, which is so frightening, is internal to what we traditionally call healthcare. But it is also accompanied by two other axes. As the WHO says, health is medical, psychological and social. The health axis, as we understand it, is medical. But there is also psychology. We are experiencing this with Covid, we have experienced it with mass tragedies, like the 2015 attacks on our territory. Finally, the social axis. Health is inseparable from our social environment and our integration into society, especially for the most precarious and vulnerable among us. It's for them that we need to make the most connections, and for whom digital tools are also the most useful.This fragmentation is therefore manifold. Let's take up the challenge together, in a coordinated way, to prove our good will. Digital tools will help us achieve this, because they are the best levers for defragmentation of the healthcare system, provided that their genesis, this co-design of innovation, is already shared by patients, by healthcare professionals, with the manufacturers who bring us the solutions.&nbsp;&nbsp;What role does Future4care play?Patients are at the heart of the system. There can be no innovation without co-designing it with them, because they will be using these innovations for their own health. This co-construction is Future4care's DNA. It's only once everyone agrees and comes together that we'll be able to implement these new solutions, which are first and foremost intended for patients and all citizens who want to preserve their health throughout their lives. In order to achieve this, we intend to involve healthcare professionals alongside the patient community from the outset. All of this, with those who are capable of providing solutions at the center, i.e. the entrepreneurs. They are there to bring us their creative intelligence and their ability to find solutions to our questions, as healthcare professionals, and to the questions of our patients.&nbsp;&nbsp;

The healthcare system is a rich and complex ecosystem.

22 start-ups join the first Future4care class

Future4care, Europe's leading gas pedal of digital healthcare start-ups, is partnering with Galen Growth, the only digital healthcare innovation specialist bringing together the world's most successful start-ups with leading organizations to accelerate innovation focused on customers, patients and healthcare professionals.Published on December 02nd, 2021 at 10:16 amSupported by a team of experienced experts, Galen Growth is committed to ensuring the success of Future4Care, its companies and partners, in order to build and develop the European digital health ecosystem together.Over the past six years, Galen Growth has established the world's largest network of digital health investors, companies and start-ups. Galen Growth has enabled numerous corporate venture capital programs to benefit from unique solutions, including HealthTech Alpha, the world's largest on-demand data and analytics platform for the private digital health market. Galen Growth has provided its partners - pharmaceuticals, medical devices, insurers and investment funds - with a decisive advantage through tailored studies to drive their digital health-focused engagements worldwide.Galen Growth is recognized on the global marketplace for its highly sought-after thought leadership publications and bespoke events, including the highest-quality Global HealthTech Summit.Galen Growth, with its team of European experts, will support Future4Care's gas pedal partners with unrivalled data to quickly identify and track the most suitable partnerships; by providing its institute with the industry's best thematic digital health research to make winning decisions; and by co-organizing highly relevant events to reach and build a wider global community."The digital health ecosystem in Western Europe is robust with nearly 2,000 companies, growing at a CAGR of ~9% since 2016. This ecosystem has attracted over US$11 billion in venture capital funding, but has the potential for much more with the right catalysts. We believe Galen Growth's partnership with Future4Care will be that catalyst!" Julien de Salaberry, CEO and founder of Galen Growth, said."Data is at the heart of the added value we bring to start-ups at Future4care. The partnership with Galen Growth is not only a plus for developing the ecosystem we're building, but also proves our ability to bring, to start-ups, the best possible expertise to accelerate the go-to-market stage through customized and tailored approaches. I'm delighted to be working with Galen Growth to ensure that advances in digital healthcare become a reality very quickly", said Agnès De Leersnyder, CEO of Future4care.Further information at <a target="_blank" rel="" href="http://www.future4care.com">www.future4care.com</a> and <a target="_blank" rel="" href="https://www.galengrowth.com">https://www.galengrowth.com</a>

Future4care joins forces with Galen Growth to accelerate digital healthcare innovation in Europe.

Laurent Frigara, co-founder of Enovacom, shares his vision and advice for taking full advantage of digital data in the world of healthcare.Published on November 25th, 2021 at 09:17 amData, the keystone of e-health!It's an indisputable fact. Harnessing the wealth of healthcare data will revolutionize the way we care for patients. It's the basis of the "5Ps" of digital medicine: more personalized, preventive, predictive, participative and evidence-based.&nbsp;Rather than argue about the potential, which you've all already clearly identified, the idea here is to understand how to move from intuition to action. To do this, we spoke to a specialist in the subject.&nbsp;Laurent Frigara, co-founder of Enovacom, the French leader in medical interoperability and an early supporter of Future4care's development.In charge of Orange Business Services' healthcare division, Enovacom currently employs over 250 healthcare experts.Here, he talks to us about sharing culture, interoperability and methodology.&nbsp;A little backgroundToday's healthcare professionals expect the right data at the right time, for the right patient. This is the foundation on which the entire medical decision chain is built. Whether it's about test results, vital signs from biomedical devices and sensors, prescription histories or health episodes, sharing this information is essential. This sharing ensures better patient care and improved care coordination, while avoiding the redundancy of examinations already carried out.&nbsp;&nbsp;The challenge is also to exploit health data in a consolidated way and in very large quantities. For example, using data from large cohorts of patients with common characteristics opens up interesting prospects and promising advances for healthcare and medical research. We can detect the emergence of certain diseases at an early stage, speed up diagnosis and evaluate the effects of medical treatment with greater precision.Data is also the raw material for AI learning. The quality and performance of an AI is directly linked to the quantity and quality of the data used.&nbsp;On a facility scale, the effective use of data from its IS enables it to optimize its operations, and thus improve care by adapting processes based on concrete elements.&nbsp;Proportionally, data consolidation is more important at regional level. It enables us to adapt health policy or, as we saw during the health crisis, fight effectively against a pandemic.&nbsp;At the same time, there's no denying that health data is also coveted for less virtuous purposes. They are so precise and personal that, for example, they can easily be used for identity theft. It can be traded at a premium on the dark web, or used to ransom healthcare facilities.&nbsp;With this in mind, we'd like to share with you five essential lessons for the successful digital transformation of your company, institution or other healthcare structure, with an effective, reliable data strategy at its heart, at the service of healthcare.&nbsp;N°1 Dealing with market constraintsMore than anywhere else, the healthcare sector faces multiple constraints, whether from an organizational, regulatory or economic point of view. Today's healthcare establishments, which produce and manage vast quantities of data, have inadequate information systems, and their transformation is slow in coming. Most of them are made up of several application layers from different generations, ten, fifteen or even twenty years ago. Under these conditions, data sharing is much more difficult.&nbsp;Historically, French doctors have rarely been inclined to share patient information. This culture of sensitive, anonymous and exclusive data locks usable data into information silos that are not conducive to exchange and sharing.&nbsp;&nbsp;What's more, it's the patient who owns his or her data. When they give their consent for their personal information to be used, they do so within a certain framework, which can sometimes hinder the use or consolidation of existing databases.&nbsp;&nbsp;To remedy this, healthcare players need to work on information systems, to make them interoperable and standardized, based on common frames of reference. To optimize the use of healthcare data, we need to ensure that it is properly collected, structured and of sufficient quality. It is also necessary to adapt processes that integrate patients consent, so as to obtain a clear vision of where the data comes from and how it will be used.&nbsp;&nbsp;N°2 Learning to structure and communicateWe need to create optimal conditions for these exchanges, both in terms of security, trust, and the ability to share reference systems to better understand each other. It is therefore necessary to put in place a technical foundation that is standardized, common, understood, integrated and shared by all players. Enovacom has been working in this field for 20 years, and it is also one of the missions of the French National Health Agency, which, through financial aid from the Ségur de la Santé, is accelerating this harmonization. This deliberate drive by the French government is an opportunity to ensure that the information systems of all healthcare organizations are based on the same standards.&nbsp;The digital solutions of the various players need to communicate with each other, if not natively, through dedicated complementary services. This will also enable them to exploit the structured data contained in healthcare documents, to offer users even greater relevance.&nbsp;However, incumbent publishers in the ecosystem do not make their often proprietary databases easily accessible. Interoperability services, whether on site or in the cloud, can break down these silos by positioning themselves in an agnostic way.&nbsp;When it comes to upgrading their information systems, healthcare establishments need to ensure that future healthcare devices, applications and software are interoperable by their very nature, and that the data they generate can be exploited. In other words, the healthcare data generated by these new elements of the healthcare ecosystem must be stored in structured data warehouses, based on common repositories. Everyone needs to speak the same language if they are to make the most of the data they collect. &nbsp;&nbsp;N°3 Be methodicalUnfortunately, knowing how to juggle with market constraints and initiating an open approach are not enough. A great deal of care needs to be taken at every stage of the data journey to prevent it from losing its value. If just one stage is not carried out correctly, the data is no longer qualified and therefore unusable. Meticulous care is therefore required, from inputting data into care production software, or sampling vital data from biomedical equipment, right through to storage in a suitable database.&nbsp;This means providing caregivers with ergonomic software natively designed to store data that can be used. Tool training is also essential to ensure the quality of the information entered.&nbsp;In addition to standardizing data syntax for sharing and consolidation, it is also important to work on semantics. In the first instance, this concerns the definition of the message: its nature, type and format, so that it can be understood by all.Semantics concern the medical content of this data, and require the sharing of semantic interoperability repositories. &nbsp;The Systematized Nomenclature of Medicine - Clinical Terms (SNOMED CT) is a key terminology for meeting these challenges. It is an international descriptive terminology covering the widest range of clinical specialties and operational needs. It standardizes the capture, classification and sharing of any clinical information by healthcare professionals.Data quality control tools also exist, to ensure that the data exchanged complies with these different standards and repositories. One example is Enovacom's work on the SI-DEP project, where its solutions analyze and control the structure and semantics of data transmitted by analysis laboratories.&nbsp;&nbsp;N°4 Generalize interoperabilityWe can't talk about digital health without addressing the issue of interoperability. Interoperability refers to the ability of different digital systems, applications and services to communicate and interact with each other. In particular, it enables patient information to be shared throughout the patient’s journey. Interoperability also facilitates the integration of innovative solutions or services into an existing establishment or ecosystem. Ultimately, this helps secure the care process, simplify procedures for patients, improve the relevance of medical decisions and ensure more effective prevention, etc.The many digital solutions used by healthcare professionals need to be interoperable, not only with each other, but also with government services such as the Personal Medical File, the Digital Health Space, regional platforms, and data warehouses such as Health Data Hub.Interoperability is also a key factor in the exploitation of healthcare data. It enables data to be extracted or consolidated from existing systems to feed data warehouses, and repositories to be shared to ensure that everyone speaks the same language.&nbsp;&nbsp;N°5 Data at the heart of Future4care's business modelIt's important for players in the ecosystem to be supported by specialists in collecting, storing and using healthcare data.&nbsp;&nbsp;Future4care's ambition is to support start-ups in bringing their innovative solutions to the market faster.&nbsp;&nbsp;In addition to providing exclusive, qualified data, Future4care supports European start-ups throughout the lifecycle of their solutions. We enable them to focus on their core added value or differentiator, as they often have little time to break through and competition is fierce. Thanks to Future4care, they can call on the best experts for all matters relating to infrastructures, security, regulations or data exploitation tools. Its members, starting with three of its historical members Orange, Sanofi and Generali, will offer their own skills, but other experts will also be called upon to contribute to the project.&nbsp;Future4care can also support start-ups in the development of their solutions, so that they are based on standards and infrastructures that will make them sustainable. We will also facilitate the integration of their applications or services into the existing ecosystem, thanks to the interoperability expertise of our members.&nbsp;&nbsp;Finally, we support start-ups in using the data made available to them by Orange, Sanofi, Generali, Capgemini and our future members. This is not only to guarantee optimal exploitation, but also to ensure that they do so in compliance with patient rights and ethics.&nbsp;Are you a start-up and would like to benefit from this support? Are you a major corporation and share our vision? Or are you a healthcare center, patient association or academic and would like to innovate alongside us? Write to us in reply to this email and let's have a chat.

Data, the keystone of e-health!

We are delighted to officially welcome our Vice President, Olivier Guérin.Published on September 30th, 2021 at 08:44 am&nbsp;PRESS RELEASESeptember 2021Future4care, Europe's leading gas pedal of digital healthcare start-ups, appoints Professor Olivier Guérin as Vice-President.Paris, September 30th, 2021 - Future4Care welcomes Olivier Guérin, Professor of Geriatrics, as Vice President. Working with Future4Care's operational team, Olivier Guérin's ambition is to support the development of this European digital healthcare ecosystem.&nbsp;Head of the Geriatrics Department at Nice University Hospital, Olivier Guérin is also a university professor. With his teams, he is developing the digital theme for Health and Autonomy, with the creation of evaluation and experimentation platforms grouped within the Health Innovation and Usage Center. He leads national action in this digital and silver eco context within France Silver Eco (FSE), of which he is 1st vice-president. From 2014 to 2020, he was deputy mayor of Nice, responsible for health, autonomy and the silver economy, and a metropolitan councilor.Olivier Guérin is also the President of the Société Française de Gériatrie et Gérontologie, a learned society specialized in the study of problems affecting the elderly and aging people.In addition, Olivier Guérin is a member of the Scientific Council responsible for informing government decisions on the Covid-19 crisis.&nbsp;His unique combination of experience in healthcare, academia, digital technology and public policy enables him to fully grasp all the challenges of e-health.I'm delighted to welcome Olivier Guérin to our team. I'm convinced that he will make a major contribution to Future4care's development and reputation, thanks to his expertise and forward-looking vision of the e-health sector. His public sector background and knowledge of the private sector are also essential assets for us in defragmenting the sector and fostering the emergence and development of a multidisciplinary ecosystem. As Vice-President of Future4Care, Olivier Guérin's role with the team is to define the themes of calls for projects, to identify and support start-ups, thanks to his proximity to hospital and academic circles and his roots in the ecosystem, and to represent Future4care at major events linked to healthcare and digital health.affirms Philippe Peyre, Chairman of Future4care.Olivier Guérin will also put his expertise and network at the service of the Future4care Institute, which will offer its members a series of conferences, training courses and work through its own Think Tank.Read Olivier Guérin's comments on his appointment <a target="_blank" rel="" href="https://x.com/Future4care/status/1443466505514061827">here.</a>For more information: <a target="_blank" rel="" href="http://www.future4care.com">www.future4care.com</a>

Professor Olivier Guérin appointed Vice-President of Future4care

A big step for Future4care...Published on September 20th, 2021 at 09:01 Vincent PurenA few months ago, Future4Care announced its creation and entry into the European e-health market. On September 22, 2021, a new milestone will be reached with the launch of our start-up gas pedal's first call for projects. This highlight will take place during France Digital Day, France's largest business meeting place for startups, financiers and manufacturers.From the Musée des Art Forains in Paris, we'll have the pleasure of launching this first call for projects, focusing on two themes: personalized medicine and remote medicine. This will be followed by a meeting session with a selection of e-health entrepreneurs from the France Digital network.&nbsp;What is France Digital?France Digital is an association of 1,800 French and European digital entrepreneurs and investors. Its board is made up of well-known investors and entrepreneurs such as Benoist Grossmann of the Eurazeo fund, Frédéric Mazzella, founder of Blablacar, Jean-David Chamboredon of the ISAI fund, Fleur Pellerin, Axel Dauchez and many others. The organization also runs France Digital Day, one of Europe's most exclusive start-up events. Each edition brings together some 3,000 start-up executives, industry c-levels, venture capitalists, opinion leaders and decision-makers from the global tech scene, from over 40 nationalities, as well as 400 VCs.&nbsp;How to apply for the Future4Care call for projects?To join the first class of our e-health start-up gas pedal, you need to meet the following four criteria. Firstly, your company must be at an intermediate level of development, close to "go to market". Secondly, your business must fall within one of the two themes on which the first promotion of our gas pedal is focusing. These are personalized medicine and remote patient care. Please note that your company's head office must be based in Europe. Finally, you must be able to justify that you are devoting 100% of your time to this project, and that you intend to make it your priority for the next few years.

Find out all the latest news from Future4care, as well as the topics that will shape tomorrow's healthcare.

In the spotlight!